

# New insights into cancer immunoediting and its three phases of equilibrium and escape

Current Opinion in Immunology

27, 16-25

DOI: [10.1016/j.coi.2014.01.004](https://doi.org/10.1016/j.coi.2014.01.004)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Chronic Mechanistic Target of Rapamycin Inhibition: Preventing Cancer to Delay Aging, or Vice Versa?. <i>Interdisciplinary Topics in Gerontology</i> , 2013, 38, 1-16.	3.6	10
2	From Genotype to Functional Phenotype: Unraveling the Metabolomic Features of Colorectal Cancer. <i>Genes</i> , 2014, 5, 536-560.	1.0	39
3	Harnessing Mechanistic Knowledge on Beneficial Versus Deleterious IFN-I Effects to Design Innovative Immunotherapies Targeting Cytokine Activity to Specific Cell Types. <i>Frontiers in Immunology</i> , 2014, 5, 526.	2.2	54
4	Plasma Stimulation of Migration of Macrophages. <i>Plasma Processes and Polymers</i> , 2014, 11, 1193-1197.	1.6	65
5	Opioids and cancer recurrence. <i>Current Opinion in Supportive and Palliative Care</i> , 2014, 8, 91-101.	0.5	59
6	Perspectives for immunotherapy in glioblastoma treatment. <i>Current Opinion in Oncology</i> , 2014, 26, 608-614.	1.1	26
7	CpG-mediated modulation of MDSC contributes to the efficacy of Ad5-TRAIL therapy against renal cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 1213-1227.	2.0	32
8	Shaping of an effective immune microenvironment to and by cancer cells. <i>Cancer Immunology, Immunotherapy</i> , 2014, 63, 991-997.	2.0	30
9	Combination immunotherapy with $\hat{\pm}$ CTLA-4 and $\hat{\pm}$ PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. , 2015, 3, 21.		157
10	Whole-Blood Gene Expression Profiles in Large-Scale Epidemiological Studies: What Do They Tell?. <i>Current Nutrition Reports</i> , 2015, 4, 377-386.	2.1	13
11	NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. , 2015, 3, 18.		51
12	Improving natural killer cell cancer immunotherapy. <i>Current Opinion in Organ Transplantation</i> , 2015, 20, 671-680.	0.8	44
13	Immunity, inflammation, and cancer: an eternal fight between good and evil. <i>Journal of Clinical Investigation</i> , 2015, 125, 3347-3355.	3.9	572
15	The Immune System in Cancer Prevention, Development and Therapy. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2015, 16, 101-107.	0.9	103
16	Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. <i>Frontiers in Immunology</i> , 2015, 6, 402.	2.2	135
17	Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses â€” Pre-Clinical Evidence and Ongoing Clinical Applications. <i>Frontiers in Immunology</i> , 2015, 6, 505.	2.2	86
18	Methylcholanthrene-Induced Sarcomas Develop Independently from NOX2-Derived ROS. <i>PLoS ONE</i> , 2015, 10, e0129786.	1.1	11
19	Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy. <i>Journal of Immunology Research</i> , 2015, 2015, 1-14.	0.9	30

#	ARTICLE	IF	CITATIONS
20	From mice to humans: developments in cancer immunoeediting. Journal of Clinical Investigation, 2015, 125, 3338-3346.	3.9	271
21	Patient-Specific Therapeutic Vaccines for Metastatic Melanoma. Oncology Issues, 2015, 30, 48-57.	0.0	3
22	Immunology and Immunotherapy in Brain Tumors " Immune Failure and Potential Counteractions. , 2015, , .		0
23	Chronic <scp>mTOR</scp> inhibition in mice with rapamycin alters <scp>T</scp>,<scp> B</scp> , myeloid, and innate lymphoid cells and gut flora and prolongs life of immune-deficient mice. Aging Cell, 2015, 14, 945-956.	3.0	94
24	Targeting the Immune System for Cancer Therapy: Lessons for Perioperative Management?. Current Anesthesiology Reports, 2015, 5, 257-267.	0.9	0
25	Human Monocytes in the Presence of Interferons Alpha2a and Gamma Are Potent Killers of Serous Ovarian Cancer Cell Lines in Combination with Paclitaxel and Carboplatin. Journal of Interferon and Cytokine Research, 2015, 35, 55-62.	0.5	11
26	Trial Watch: Peptide-based anticancer vaccines. Oncoimmunology, 2015, 4, e974411.	2.1	97
27	Early Growth Response 3 regulates genes of inflammation and directly activates IL6 and IL8 expression in prostate cancer. British Journal of Cancer, 2015, 112, 755-764.	2.9	62
28	Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE <sup>®</sup> ) antibody construct blinatumomab as a potential therapy. International Immunology, 2015, 27, 31-37.	1.8	39
29	Building immunity to cancer with radiation therapy. Cancer Letters, 2015, 368, 198-208.	3.2	69
30	In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. Vaccine, 2015, 33, 7415-7422.	1.7	142
31	Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma. British Journal of Cancer, 2015, 113, 232-241.	2.9	119
32	Inflammation and Lung Cancer. , 2015, , .		2
33	NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nature Medicine, 2015, 21, 914-921.	15.2	728
34	Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biology and Therapy, 2015, 16, 807-820.	1.5	257
35	Immune biomarkers: how well do they serve prognosis in human cancers?. Expert Review of Molecular Diagnostics, 2015, 15, 49-59.	1.5	6
36	Tumor border sharpness correlates with HLA-G expression in low-grade gliomas. Journal of Neuroimmunology, 2015, 282, 1-6.	1.1	24
38	Immunotherapy for canine cancer " Is it time to go back to the future?. Journal of Small Animal Practice, 2015, 56, 229-241.	0.5	8

#	ARTICLE	IF	CITATIONS
39	Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer. Expert Opinion on Biological Therapy, 2015, 15, 1093-1099.	1.4	55
40	The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies. Cancer Immunology Research, 2015, 3, 436-443.	1.6	631
41	On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Science Translational Medicine, 2015, 7, 280sr1.	5.8	134
42	Strategies to Target Tumor Immunosuppression. , 2015, , 73-86.		0
43	Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma. OncoImmunology, 2015, 4, e1001236.	2.1	22
44	Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors. Cancer Immunology Research, 2015, 3, 1344-1355.	1.6	285
45	Innate Lymphoid Cells in Cancer. Cancer Immunology Research, 2015, 3, 1109-1114.	1.6	30
46	<i>In vivo</i> profiling reveals immunomodulatory effects of sorafenib and dacarbazine on melanoma. OncoImmunology, 2015, 4, e988458.	2.1	12
47	Evolution of metastasis revealed by mutational landscapes of chemically induced skin cancers. Nature Medicine, 2015, 21, 1514-1520.	15.2	93
48	Relevance of tumor-infiltrating lymphocytes in breast cancer. BMC Medicine, 2015, 13, 202.	2.3	177
49	Understanding the Rationale for Immunotherapy in Non-Small Cell Lung Cancer. Seminars in Oncology, 2015, 42, S3-S10.	0.8	96
50	Convergence of Acquired Mutations and Alternative Splicing of <i>CD19</i> Enables Resistance to CART-19 Immunotherapy. Cancer Discovery, 2015, 5, 1282-1295.	7.7	997
51	Myeloid <i>STAT3</i> promotes formation of colitis-associated colorectal cancer in mice. OncoImmunology, 2015, 4, e998529.	2.1	24
52	Immunological landscape and immunotherapy of hepatocellular carcinoma. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 681-700.	8.2	478
53	Nanoparticulate immunotherapy for cancer. Journal of Controlled Release, 2015, 219, 167-180.	4.8	80
54	$\beta$ 1 T cells in cancer. Nature Reviews Immunology, 2015, 15, 683-691.	10.6	464
55	The Dynamics of Interactions Among Immune and Glioblastoma Cells. NeuroMolecular Medicine, 2015, 17, 335-352.	1.8	30
56	Are BiTEs the "missing link" in cancer therapy?. OncoImmunology, 2015, 4, e1008339.	2.1	59

#	ARTICLE	IF	CITATIONS
57	Immunology and Immunotherapy of Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 3293-3304.	0.8	566
59	MMR deficiency may lead to a high immunogenicity and then an improvement in anti-PD-1 efficacy for metastatic colorectal cancer. <i>Immunotherapy</i> , 2015, 7, 1133-1134.	1.0	9
60	Combination of Radiotherapy and Immune Checkpoint Inhibitors. <i>Seminars in Radiation Oncology</i> , 2015, 25, 28-33.	1.0	121
61	Genomic Instability and Cancer Metastasis. <i>Cancer Metastasis - Biology and Treatment</i> , 2015, , .	0.1	1
62	The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. <i>Annals of Oncology</i> , 2015, 26, 259-271.	0.6	2,122
63	Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. <i>International Immunology</i> , 2015, 27, 39-46.	1.8	286
64	Immuno-oncology combinations: raising the tail of the survival curve. <i>Cancer Biology and Medicine</i> , 2016, 13, 171-193.	1.4	98
65	Prognostic significance of PD-L1 expression in patients with gastric cancer in East Asia: a meta-analysis. <i>OncoTargets and Therapy</i> , 2016, 9, 2649.	1.0	28
66	Importance of tumor infiltrating lymphocytes in non-small cell lung cancer?. <i>Annals of Translational Medicine</i> , 2016, 4, 142-142.	0.7	6
67	Immunological battlefield in gastric cancer and role of immunotherapies. <i>World Journal of Gastroenterology</i> , 2016, 22, 6373.	1.4	33
68	The Immune System in Cancer Pathogenesis: Potential Therapeutic Approaches. <i>Journal of Immunology Research</i> , 2016, 2016, 1-13.	0.9	153
69	Technical Considerations for the Generation of Adoptively Transferred T Cells in Cancer Immunotherapy. <i>Cancers</i> , 2016, 8, 86.	1.7	6
70	Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice. <i>Frontiers in Cell and Developmental Biology</i> , 2016, 4, 64.	1.8	45
71	Tumor Microenvironment Metabolism: A New Checkpoint for Anti-Tumor Immunity. <i>Vaccines</i> , 2016, 4, 46.	2.1	87
72	The Janus Face of Death Receptor Signaling during Tumor Immunoediting. <i>Frontiers in Immunology</i> , 2016, 7, 446.	2.2	42
73	HZE Radiation Non-Targeted Effects on the Microenvironment That Mediate Mammary Carcinogenesis. <i>Frontiers in Oncology</i> , 2016, 6, 57.	1.3	29
74	Hypothesis: The Intratumoral Immune Response against a Cancer Progenitor Cell Impacts the Development of Well-Differentiated versus Dedifferentiated Disease in Liposarcoma. <i>Frontiers in Oncology</i> , 2016, 6, 134.	1.3	2
75	Cancer Immunosurveillance: Immunoediting. , 2016, , 396-405.		3

#	ARTICLE	IF	CITATIONS
76	Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?. <i>Antibodies</i> , 2016, 5, 1.	1.2	34
77	A Perspective of Immunotherapy for Prostate Cancer. <i>Cancers</i> , 2016, 8, 64.	1.7	28
78	Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study. <i>BMC Cancer</i> , 2016, 16, 823.	1.1	25
79	PD-L1 expression in human cancers and its association with clinical outcomes. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5023-5039.	1.0	558
80	Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?. <i>Cancer Treatment Reviews</i> , 2016, 48, 61-68.	3.4	102
81	High expression of CD39 in gastric cancer reduces patient outcome following radical resection. <i>Oncology Letters</i> , 2016, 12, 4080-4086.	0.8	42
82	Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. <i>Cell</i> , 2016, 167, 1540-1554.e12.	13.5	830
83	Unraveling the role of preexisting immunity in prostate cancer patients vaccinated with a HER-2/neu hybrid peptide. , 2016, 4, 75.		11
85	Immunogenicity of self tumor associated proteins is enhanced through protein truncation. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16030.	2.0	3
86	Non-small cell lung cancer is characterised by a distinct inflammatory signature in serum compared with chronic obstructive pulmonary disease. <i>Clinical and Translational Immunology</i> , 2016, 5, e109.	1.7	26
87	Dendritic cell vaccines for melanoma: past, present and future. <i>Melanoma Management</i> , 2016, 3, 273-289.	0.1	20
88	Translational immunotoxicology of immunomodulatory monoclonal antibodies. <i>Drug Discovery Today: Technologies</i> , 2016, 21-22, 85-93.	4.0	4
89	STAT1-associated intratumoural T <sub>H</sub> 1 immunity predicts chemotherapy resistance in high-grade serous ovarian cancer. <i>Journal of Pathology: Clinical Research</i> , 2016, 2, 259-270.	1.3	42
90	Immune Monitoring Using mRNA-Transfected Dendritic Cells. <i>Methods in Molecular Biology</i> , 2016, 1428, 245-259.	0.4	3
92	Cellular Adjuvant Properties, Direct Cytotoxicity of Re-differentiated V $\alpha$ 24 Invariant NKT-like Cells from Human Induced Pluripotent Stem Cells. <i>Stem Cell Reports</i> , 2016, 6, 213-227.	2.3	66
93	Targeting of cancer neoantigens with donor-derived T cell receptor repertoires. <i>Science</i> , 2016, 352, 1337-1341.	6.0	414
94	A comprehensive profile of recurrent glioblastoma. <i>Oncogene</i> , 2016, 35, 5819-5825.	2.6	169
95	Low density of FOXP3-positive T cells in normal colonic mucosa is related to the presence of beta2-microglobulin mutations in Lynch syndrome-associated colorectal cancer. <i>Oncolimmunology</i> , 2016, 5, e1075692.	2.1	28

#	ARTICLE	IF	CITATIONS
96	Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. <i>Leukemia and Lymphoma</i> , 2016, 57, 1021-1032.	0.6	119
97	Human leukocyte antigen-G overexpression predicts poor clinical outcomes in low-grade gliomas. <i>Journal of Neuroimmunology</i> , 2016, 294, 27-31.	1.1	11
98	Reverse immunoediting: When immunity is edited by antigen. <i>Immunology Letters</i> , 2016, 175, 16-20.	1.1	21
99	The Immune Biology of Microsatellite-Unstable Cancer. <i>Trends in Cancer</i> , 2016, 2, 121-133.	3.8	193
100	Leprosy as a model to understand cancer immunosurveillance and T cell anergy. <i>Journal of Leukocyte Biology</i> , 2016, 100, 47-54.	1.5	7
101	Treatment of Renal Cell Cancer With Programmed Cell Death 1 Blockade. <i>JAMA Oncology</i> , 2016, 2, 1186.	3.4	0
102	HESI/FDA workshop on immunomodulators and cancer risk assessment: Building blocks for a weight-of-evidence approach. <i>Regulatory Toxicology and Pharmacology</i> , 2016, 75, 72-80.	1.3	13
103	NLRC5/MHC class I transactivator is a target for immune evasion in cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 5999-6004.	3.3	198
104	Present Yourself! By MHC Class I and MHC Class II Molecules. <i>Trends in Immunology</i> , 2016, 37, 724-737.	2.9	566
105	The genomic landscape of breast cancer and its interaction with host immunity. <i>Breast</i> , 2016, 29, 241-250.	0.9	194
106	Chemical JAK inhibitors for the treatment of rheumatoid arthritis. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 2215-2225.	0.9	22
107	BPTF Depletion Enhances T-cell-Mediated Antitumor Immunity. <i>Cancer Research</i> , 2016, 76, 6183-6192.	0.4	24
108	The immune system and cancer evasion strategies: therapeutic concepts. <i>Journal of Internal Medicine</i> , 2016, 279, 541-562.	2.7	212
109	Immunogenic, cellular, and angiogenic drivers of tumor dormancy—a melanoma view. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 27-42.	1.5	33
110	Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , .	0.1	2
111	Clinical Implications of Hepatocyte Growth Factor, Interleukin-20, and Interleukin-22 in Serum and Bronchoalveolar Fluid of Patients with Non-Small Cell Lung Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2016, 952, 41-49.	0.8	17
112	Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis. <i>BioDrugs</i> , 2016, 30, 407-419.	2.2	52
113	Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC). <i>Expert Opinion on Emerging Drugs</i> , 2016, 21, 243-254.	1.0	5

#	ARTICLE	IF	CITATIONS
114	Neoantigens encoded in the cancer genome. <i>Current Opinion in Immunology</i> , 2016, 41, 98-103.	2.4	65
115	DAMP-Induced Allograft and Tumor Rejection: The Circle Is Closing. <i>American Journal of Transplantation</i> , 2016, 16, 3322-3337.	2.6	61
116	Immunotherapy in Lung Cancer. <i>Cancer Treatment and Research</i> , 2016, 170, 203-223.	0.2	8
117	Tailored Tumor Immunogenicity Reveals Regulation of CD4 and CD8 T Cell Responses against Cancer. <i>Cell Reports</i> , 2016, 17, 2234-2246.	2.9	57
118	Disruption of Anti-tumor T Cell Responses by Cancer-Associated Fibroblasts. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , 77-98.	0.1	1
119	PD-1/PD-L1 expression in extra-medullary lesions of multiple myeloma. <i>Leukemia Research</i> , 2016, 49, 98-101.	0.4	7
120	Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1209-1223.	1.4	18
121	Immune cell recruitment in teratomas is impaired by increased Wnt secretion. <i>Stem Cell Research</i> , 2016, 17, 607-615.	0.3	32
122	BTLA identifies dysfunctional PD-1-expressing CD4 <sup>+</sup> T cells in human hepatocellular carcinoma. <i>Oncolmmunology</i> , 2016, 5, e1254855.	2.1	36
123	Trametinib Drives T-cell-Dependent Control of KRAS-Mutated Tumors by Inhibiting Pathological Myelopoiesis. <i>Cancer Research</i> , 2016, 76, 6253-6265.	0.4	46
124	Overexpression of CD39 in hepatocellular carcinoma is an independent indicator of poor outcome after radical resection. <i>Medicine (United States)</i> , 2016, 95, e4989.	0.4	52
125	Adjuvant-Loaded Subcellular Vesicles Derived From Disrupted Cancer Cells for Cancer Vaccination. <i>Small</i> , 2016, 12, 2321-2333.	5.2	39
126	Harnessing T cells to fight cancer with BiTE antibody constructs – past developments and future directions. <i>Immunological Reviews</i> , 2016, 270, 193-208.	2.8	126
127	Harnessing the immune system in acute myeloid leukaemia. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 103, 62-77.	2.0	90
128	Neoantigen landscape dynamics during human melanoma T cell interactions. <i>Nature</i> , 2016, 536, 91-95.	13.7	387
129	Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy. <i>Breast Care</i> , 2016, 11, 102-107.	0.8	35
130	Large-scale microarray profiling reveals four stages of immune escape in non-Hodgkin lymphomas. <i>Oncolmmunology</i> , 2016, 5, e1188246.	2.1	43
131	Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency. <i>Cancer Research</i> , 2016, 76, 4347-4358.	0.4	63



#	ARTICLE	IF	CITATIONS
132	Progress in understanding the safety and efficacy of Janus kinase inhibitors for treatment of rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 1047-1057.	1.3	33
133	Checkpoint Antibodies but not T Cell-Recruiting Diabodies Effectively Synergize with TIL-Inducing $\beta$ -Irradiation. <i>Cancer Research</i> , 2016, 76, 4673-4683.	0.4	60
134	Erythropoietin increases macrophage-mediated T cell suppression. <i>Cellular Immunology</i> , 2016, 306-307, 17-24.	1.4	16
135	Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 2640-2648.	1.4	36
136	Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells. <i>Leukemia</i> , 2016, 30, 1805-1815.	3.3	32
138	Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms. <i>Future Oncology</i> , 2016, 12, 551-564.	1.1	8
139	Clinical trials exploring the benefit of immunotherapy and radiation in cancer treatment: A review of the past and a look into the future. <i>Current Problems in Cancer</i> , 2016, 40, 38-67.	1.0	9
140	Innovative perspectives of immunotherapy in head and neck cancer. From relevant scientific rationale to effective clinical practice. <i>Cancer Treatment Reviews</i> , 2016, 43, 113-123.	3.4	9
141	Antibodies as stratagems against cancer. <i>Molecular BioSystems</i> , 2016, 12, 2047-2055.	2.9	14
142	Toward Personalized Lymphoma Immunotherapy: Identification of Common Driver Mutations Recognized by Patient CD8+ T Cells. <i>Clinical Cancer Research</i> , 2016, 22, 2226-2236.	3.2	26
143	Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. <i>Nature Reviews Rheumatology</i> , 2016, 12, 25-36.	3.5	468
144	Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2016, 17, 263-270.e2.	1.1	107
145	History of chickenpox in glioma risk: a report from the glioma international case-control study (<sc>GICC</sc>). <i>Cancer Medicine</i> , 2016, 5, 1352-1358.	1.3	36
146	The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer. <i>Advances in Immunology</i> , 2016, 130, 25-74.	1.1	181
147	STAT5 Is a Key Regulator in NK Cells and Acts as a Molecular Switch from Tumor Surveillance to Tumor Promotion. <i>Cancer Discovery</i> , 2016, 6, 414-429.	7.7	124
148	RNAi nanomaterials targeting immune cells as an anti-tumor therapy: the missing link in cancer treatment?. <i>Materials Today</i> , 2016, 19, 29-43.	8.3	31
149	The immune mechanisms of abscopal effect in radiation therapy. <i>Current Problems in Cancer</i> , 2016, 40, 10-24.	1.0	131
150	Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis. <i>Cancer Research</i> , 2016, 76, 1746-1756.	0.4	164

#	ARTICLE	IF	CITATIONS
151	C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. <i>Nature Communications</i> , 2016, 7, 10346.	5.8	224
152	The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 789-800.	0.5	401
153	Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies. <i>Journal of Thoracic Oncology</i> , 2016, 11, 524-536.	0.5	48
154	Identification of a highly immunogenic mouse breast cancer sub cell line, 4T1-S. <i>Human Cell</i> , 2016, 29, 58-66.	1.2	14
155	MYC regulates the antitumor immune response through CD47 and PD-L1. <i>Science</i> , 2016, 352, 227-231.	6.0	989
156	Immunosuppressive cells in tumor immune escape and metastasis. <i>Journal of Molecular Medicine</i> , 2016, 94, 509-522.	1.7	270
157	Novel avenues in immunotherapies for colorectal cancer. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 465-480.	1.4	9
158	Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 779-786.	2.0	129
159	Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer. <i>Annals of Oncology</i> , 2016, 27, 249-256.	0.6	125
160	Immunologic approaches to cancer prevention—current status, challenges, and future perspectives. <i>Seminars in Oncology</i> , 2016, 43, 161-172.	0.8	35
161	Sialic acids in cancer biology and immunity. <i>Glycobiology</i> , 2016, 26, 111-128.	1.3	364
162	Differences in the composition of the immune infiltrate in breast cancer, colorectal carcinoma, melanoma and non-small cell lung cancer: A microarray-based meta-analysis. <i>Oncotarget</i> , 2016, 5, e1067746.	2.1	10
163	Key mechanisms involved in ionizing radiation-induced systemic effects. A current review. <i>Toxicology Research</i> , 2016, 5, 12-33.	0.9	71
164	The good and the bad faces of STAT1 in solid tumours. <i>Cytokine</i> , 2017, 89, 12-20.	1.4	191
165	Tyrosine kinase 2—Surveillant of tumours and bona fide oncogene. <i>Cytokine</i> , 2017, 89, 209-218.	1.4	45
166	Coevolution of Leukemia and Host Immune Cells in Chronic Lymphocytic Leukemia. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2017, 7, a026740.	2.9	25
167	Differentiated State of Initiating Tumor Cells Is Key to Distinctive Immune Responses Seen in H-RasG12V-Induced Squamous Tumors. <i>Cancer Immunology Research</i> , 2017, 5, 198-210.	1.6	7
168	Targeting the Lung Cancer Microenvironment: Harnessing Host Responses. , 2017, , 309-327.		1

#	ARTICLE	IF	CITATIONS
169	Experimental animal modeling for immuno-oncology. , 2017, 173, 34-46.		44
170	Breast Cancer Immunology and Immunotherapy. International Review of Cell and Molecular Biology, 2017, 331, 1-53.	1.6	47
171	Radiotherapy and immunotherapy: a beneficial liaison?. Nature Reviews Clinical Oncology, 2017, 14, 365-379.	12.5	760
172	PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective. Journal of Hematology and Oncology, 2017, 10, 34.	6.9	82
173	MYC: Master Regulator of Immune Privilege. Trends in Immunology, 2017, 38, 298-305.	2.9	70
174	Targeting neoantigens to augment antitumour immunity. Nature Reviews Cancer, 2017, 17, 209-222.	12.8	724
175	Tumor Microenvironment and Differential Responses to Therapy. Cold Spring Harbor Perspectives in Medicine, 2017, 7, a026781.	2.9	278
177	Annexin A1 influences in breast cancer: Controversies on contributions to tumour, host and immunoediting processes. Pharmacological Research, 2017, 119, 278-288.	3.1	25
178	JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs, 2017, 77, 521-546.	4.9	711
179	Tumor-infiltrating lymphocytes are significantly associated with better overall survival and disease-free survival in triple-negative but not estrogen receptor-positive breast cancers. Human Pathology, 2017, 64, 7-12.	1.1	64
180	HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance. Oncoimmunology, 2017, 6, e1171447.	2.1	64
181	Microparticles shed from multidrug resistant breast cancer cells provide a parallel survival pathway through immune evasion. BMC Cancer, 2017, 17, 104.	1.1	36
182	Metronomic chemotherapy and immunotherapy in cancer treatment. Cancer Letters, 2017, 400, 282-292.	3.2	116
183	Coexpressed modular gene expression reveals inverse correlation between immune responsive transcription and aggressiveness in gastric tumours. Cancer Immunology, Immunotherapy, 2017, 66, 941-954.	2.0	2
184	PD-L1/PD-1 check-point in gastric carcinoma with lymphoid stroma case report with immunochemical study. Medicine (United States), 2017, 96, e5730.	0.4	4
185	Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treatment Reviews, 2017, 52, 71-81.	3.4	437
186	IGFBP7 Deletion Promotes Hepatocellular Carcinoma. Cancer Research, 2017, 77, 4014-4025.	0.4	44
187	Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients. Oncoimmunology, 2017, 6, e1323618.	2.1	42

#	ARTICLE	IF	CITATIONS
188	Immunotherapeutic approaches of IL-1 neutralization in the tumor microenvironment. <i>Journal of Leukocyte Biology</i> , 2017, 102, 293-306.	1.5	40
189	Advancing Immunotherapy in Metastatic Breast Cancer. <i>Current Treatment Options in Oncology</i> , 2017, 18, 35.	1.3	13
191	A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 5055-5065.	3.2	62
192	Qa-2 expression levels is related with tumor-infiltrating lymphocytes profile during solid Ehrlich tumor development. <i>Biomedicine and Pharmacotherapy</i> , 2017, 92, 750-756.	2.5	4
193	Cytomegalovirus vector expressing RAE1 <sup>3</sup> induces enhanced anti-tumor capacity of murine CD8 <sup>+</sup> T cells. <i>European Journal of Immunology</i> , 2017, 47, 1354-1367.	1.6	18
194	New insights into the role of EMT in tumor immune escape. <i>Molecular Oncology</i> , 2017, 11, 824-846.	2.1	332
195	Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma. <i>Cancer Discovery</i> , 2017, 7, 630-651.	7.7	48
196	Immune checkpoint inhibition and its relationship with hypermutation phenotype as a potential treatment for Glioblastoma. <i>Journal of Neuro-Oncology</i> , 2017, 132, 359-372.	1.4	8
197	Frequency and functional characterization of exhausted CD8 <sup>+</sup> T cells in chronic lymphocytic leukemia. <i>European Journal of Haematology</i> , 2017, 98, 622-631.	1.1	44
198	Programmed death ligand 1 (PD-L1) expression and tumor microenvironment: Implications for patients with oral precancerous lesions. <i>Oral Oncology</i> , 2017, 68, 36-43.	0.8	71
199	Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. <i>Lancet Oncology</i> , The, 2017, 18, 52-62.	5.1	225
200	TILs in Head and Neck Cancer: Ready for Clinical Implementation and Why (Not)?: <i>Head and Neck Pathology</i> , 2017, 11, 354-363.	1.3	67
201	Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients. <i>Oncolmmunology</i> , 2017, 6, e1260214.	2.1	11
202	Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. <i>Pathology</i> , 2017, 49, 141-155.	0.3	112
203	The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. <i>Annals of Oncology</i> , 2017, 28, 321-328.	0.6	72
204	Overexpression of immunomodulatory mediators in oral precancerous lesions. <i>Human Immunology</i> , 2017, 78, 752-757.	1.2	37
205	Evaluation of peripheral blood T lymphocyte surface activation markers and transcription factors in patients with early stage non-small cell lung cancer. <i>Cellular Immunology</i> , 2017, 322, 26-33.	1.4	14
207	Nanoparticulate Delivery of Cancer Cell Membrane Elicits Multiantigenic Antitumor Immunity. <i>Advanced Materials</i> , 2017, 29, 1703969.	11.1	392

#	ARTICLE	IF	CITATIONS
208	Cancer as an ecomolecular disease and a neoplastic consortium. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 484-499.	3.3	14
209	Acute lymphoblastic leukemia relapse after CD19-targeted chimeric antigen receptor T cell therapy. <i>Journal of Leukocyte Biology</i> , 2017, 102, 1347-1356.	1.5	40
210	Immune Checkpoint Inhibitors for the Treatment of Hepatocellular Carcinoma. , 2017, , 51-68.		0
211	Sub-clonal analysis of the murine C1498 acute myeloid leukaemia cell line reveals genomic and immunogenic diversity. <i>Immunology Letters</i> , 2017, 192, 27-34.	1.1	1
212	MicroRNAs in the Diagnosis and Treatment of Cancer. <i>Immunological Investigations</i> , 2017, 46, 880-897.	1.0	52
213	Blockade of surface-bound TGF- $\beta$ 2 on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. <i>Science Signaling</i> , 2017, 10, .	1.6	100
214	Tumor Resection Recruits Effector T Cells and Boosts Therapeutic Efficacy of Encapsulated Stem Cells Expressing IFN $\beta$ in Glioblastomas. <i>Clinical Cancer Research</i> , 2017, 23, 7047-7058.	3.2	36
215	CD155TIGIT Signaling Regulates CD8+ T-cell Metabolism and Promotes Tumor Progression in Human Gastric Cancer. <i>Cancer Research</i> , 2017, 77, 6375-6388.	0.4	218
216	Immunotherapy in managing metastatic melanoma: which treatment when?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1523-1538.	1.4	13
217	Prognostic Significance of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant Chemotherapy. <i>Pancreas</i> , 2017, 46, 1180-1187.	0.5	47
218	Skin Cancer: Genetics, Immunology, Treatments, and Psychological Care. , 2017, , 851-934.		9
219	Therapeutic Implications of Angiogenesis in Cancer. , 2017, , 171-216.		0
220	Immune profiling of melanoma tumors reflecting aggressiveness in a preclinical model. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1631-1642.	2.0	16
221	Genomic and transcriptomic heterogeneity of colorectal tumours arising in Lynch syndrome. <i>Journal of Pathology</i> , 2017, 243, 242-254.	2.1	69
222	Nutrition, inflammation and cancer. <i>Nature Immunology</i> , 2017, 18, 843-850.	7.0	313
223	Modulation of dendritic cell and T cell cross-talk during aging: The potential role of checkpoint inhibitory molecules. <i>Ageing Research Reviews</i> , 2017, 38, 40-51.	5.0	27
224	The role of the tumour microenvironment in immunotherapy. <i>Endocrine-Related Cancer</i> , 2017, 24, T283-T295.	1.6	73
225	Spontaneous CD4 <sup>+</sup> and CD8 <sup>+</sup> T $\alpha$ cell responses directed against cancer testis antigens are present in the peripheral blood of testicular cancer patients. <i>European Journal of Immunology</i> , 2017, 47, 1232-1242.	1.6	18

#	ARTICLE	IF	CITATIONS
227	Implication of chemo-resistant memory T cells for immune surveillance in patients with sarcoma receiving chemotherapy. <i>Cancer Science</i> , 2017, 108, 1739-1745.	1.7	8
228	Immunosuppressive enzymes in the tumor microenvironment. <i>FEBS Letters</i> , 2017, 591, 3135-3157.	1.3	33
229	Benefits in Disease Prevention, Control, and Cure. , 2017, , 189-243.		0
230	Human papillomavirus-driven immune deviation: challenge and novel opportunity for immunotherapy. <i>Therapeutic Advances in Vaccines</i> , 2017, 5, 69-82.	2.7	51
231	Inflammation-Related Pancreatic Carcinogenesis. <i>Pancreas</i> , 2017, 46, 973-985.	0.5	8
232	The Immunology of Melanoma. <i>Clinics in Laboratory Medicine</i> , 2017, 37, 449-471.	0.7	34
235	A high ratio of IL-12R $\beta$ 2-positive tumor-infiltrating lymphocytes indicates favorable prognosis in laryngeal cancer. <i>Oral Oncology</i> , 2017, 74, 148-156.	0.8	9
236	32nd Annual Meeting and Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC) Tj ETQq1 1 0.784314 rgBT /O	1.0	4
237	Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. <i>Nature</i> , 2017, 551, 340-345.	13.7	396
238	Postsorafenib systemic treatments for hepatocellular carcinoma: questions and opportunities after the regorafenib trial. <i>Future Oncology</i> , 2017, 13, 1893-1905.	1.1	9
239	HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. <i>British Journal of Cancer</i> , 2017, 117, 451-460.	2.9	321
240	Addressing current challenges in cancer immunotherapy with mathematical and computational modelling. <i>Journal of the Royal Society Interface</i> , 2017, 14, 20170150.	1.5	71
241	Immunological Microenvironment of Hepatocellular Carcinoma and Its Clinical Implication. <i>Oncology</i> , 2017, 92, 40-49.	0.9	100
242	A randomized trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer. <i>Annals of Oncology</i> , 2017, 28, 298-304.	0.6	37
243	Immunogenic cell death in cancer and infectious disease. <i>Nature Reviews Immunology</i> , 2017, 17, 97-111.	10.6	2,000
244	The safety of anti PD-1 therapeutics for the treatment of melanoma. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 41-53.	1.0	17
245	Friend or foe?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1867, 1-18.	3.3	54
246	Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance. <i>Annals of Oncology</i> , 2017, 28, 457-467.	0.6	27

#	ARTICLE	IF	CITATIONS
247	Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies. <i>Annals of Oncology</i> , 2017, 28, 57-74.	0.6	45
248	Prognostic Value of Tumor-Infiltrating Lymphocytes for Patients With Head and Neck Squamous Cell Carcinoma. <i>Translational Oncology</i> , 2017, 10, 10-16.	1.7	64
249	Chemical Carcinogenesis Models of Cancer: Back to the Future. <i>Annual Review of Cancer Biology</i> , 2017, 1, 295-312.	2.3	30
251	An update on the relevance of vaccine research for the treatment of metastatic melanoma. <i>Melanoma Management</i> , 2017, 4, 203-215.	0.1	8
253	Cancer Immunoprevention and Public Health. <i>Frontiers in Public Health</i> , 2017, 5, 101.	1.3	10
254	TREX1 is a checkpoint for innate immune sensing of DNA damage that fosters cancer immune resistance. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 509-515.	1.1	8
255	Immune Checkpoints as a Target for Colorectal Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1324.	1.8	112
256	Insights on the HLA-Binding Peptidome in Cancer. <i>The Enzymes</i> , 2017, 42, 81-103.	0.7	0
257	Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1660.	1.8	33
258	Advanced Strategies in Immune Modulation of Cancer Using Lipid-Based Nanoparticles. <i>Frontiers in Immunology</i> , 2017, 8, 69.	2.2	32
259	Barriers to Radiation-Induced In Situ Tumor Vaccination. <i>Frontiers in Immunology</i> , 2017, 8, 229.	2.2	149
260	Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. <i>Frontiers in Immunology</i> , 2017, 8, 267.	2.2	61
261	Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease. <i>Frontiers in Immunology</i> , 2017, 8, 513.	2.2	19
262	Natural Killer Defective Maturation Is Associated with Adverse Clinical Outcome in Patients with Acute Myeloid Leukemia. <i>Frontiers in Immunology</i> , 2017, 8, 573.	2.2	47
263	Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies. <i>Frontiers in Immunology</i> , 2017, 8, 828.	2.2	295
264	Chronic NKG2D Engagement In Vivo Differentially Impacts NK Cell Responsiveness by Activating NK Receptors. <i>Frontiers in Immunology</i> , 2017, 8, 1466.	2.2	20
265	Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives. <i>Frontiers in Immunology</i> , 2017, 8, 1526.	2.2	74
266	Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma. <i>Frontiers in Immunology</i> , 2017, 8, 1617.	2.2	43

#	ARTICLE	IF	CITATIONS
267	Harnessing the Power of Invariant Natural Killer T Cells in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2017, 8, 1829.	2.2	49
268	MAGE-A Antigens and Cancer Immunotherapy. <i>Frontiers in Medicine</i> , 2017, 4, 18.	1.2	54
269	Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions. <i>Frontiers in Oncology</i> , 2017, 7, 156.	1.3	87
270	Targeting Cancer Stem Cells and Their Niche: Current Therapeutic Implications and Challenges in Pancreatic Cancer. <i>Stem Cells International</i> , 2017, 2017, 1-9.	1.2	11
271	Immunotherapy and gene therapy as novel treatments for cancer. , 2017, v48, 138-147.		22
272	Evolutionary Perspective of Tumorigenesis and Antitumor Immunity: A Comparative Approach. , 2017, , 119-135.		1
273	Do We Need Full Donor Chimerism? How Alloreactive Cell Therapies without Substantial Engraftment Might Treat Hematologic Cancers. <i>Current Drug Targets</i> , 2017, 18, 281-295.	1.0	12
274	Analysis of the whole transcriptome from gingivo-buccal squamous cell carcinoma reveals deregulated immune landscape and suggests targets for immunotherapy. <i>PLoS ONE</i> , 2017, 12, e0183606.	1.1	10
275	Dual role of inflammatory mediators in cancer. <i>Ecancermedicalscience</i> , 2017, 11, 721.	0.6	119
276	Cellular immunity augmentation in mainstream oncologic therapy. <i>Cancer Biology and Medicine</i> , 2017, 14, 121.	1.4	8
277	BPTF inhibits NK cell activity and the abundance of natural cytotoxicity receptor co-ligands. <i>Oncotarget</i> , 2017, 8, 64344-64357.	0.8	24
278	Cancer Immunotherapy. , 2017, , 32-65.		1
279	Characteristics of circulating tumor cells in organ metastases, prognosis, and T lymphocyte mediated immune response. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 2413-2424.	1.0	16
281	Oncogenic pathways as the basis of primary immune ignorance. <i>Emerging Topics in Life Sciences</i> , 2017, 1, 421-428.	1.1	0
282	First Report of Prostate-specific Membrane Antigen-targeted Immunotherapy in Prostate Cancer: The Future is Bright. <i>European Urology</i> , 2018, 73, 653-655.	0.9	4
283	Modulation of innate and adaptive immune responses by arabinoxylans. <i>Journal of Food Biochemistry</i> , 2018, 42, e12473.	1.2	13
284	Rational combinations of in vivo cancer antigen priming and adoptive T-cell therapy mobilize immune and clinical responses in terminal cancers. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 907-915.	2.0	1
285	Targeting Neoantigens for Personalised Immunotherapy. <i>BioDrugs</i> , 2018, 32, 99-109.	2.2	11



#	ARTICLE	IF	CITATIONS
286	The possibility of cancer immune editing in gliomas. A critical review. <i>Oncolimmunology</i> , 2018, 7, e1445458.	2.1	35
287	Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review). <i>International Journal of Oncology</i> , 2018, 52, 1041-1056.	1.4	4
288	Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy. <i>Current Medical Research and Opinion</i> , 2018, 34, 903-910.	0.9	18
289	The dark side of tumor-associated endothelial cells. <i>Seminars in Immunology</i> , 2018, 35, 35-47.	2.7	82
290	Skin Diseases in the Immunosuppressed. , 2018, , .		2
291	Systemic treatments for hepatocellular carcinoma: challenges and future perspectives. <i>Hepatic Oncology</i> , 2018, 5, HEP01.	4.2	30
292	Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML. <i>Clinical Cancer Research</i> , 2018, 24, 1834-1844.	3.2	136
293	Using immunotherapy to boost the abscopal effect. <i>Nature Reviews Cancer</i> , 2018, 18, 313-322.	12.8	844
294	Cell death-based treatment of lung adenocarcinoma. <i>Cell Death and Disease</i> , 2018, 9, 117.	2.7	434
295	Impact of genomics on the surgical management of melanoma. <i>British Journal of Surgery</i> , 2018, 105, e31-e47.	0.1	3
296	The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer. <i>Breast Care</i> , 2018, 13, 16-21.	0.8	135
297	Therapeutic Strategies for Breast Cancer. , 2018, , 315-330.e7.		5
298	Modeling tumor immunity of mouse glioblastoma by exhausted CD8+ T cells. <i>Scientific Reports</i> , 2018, 8, 208.	1.6	24
299	High macrophage PD-L1 expression not responsible for T cell suppression. <i>Cellular Immunology</i> , 2018, 324, 50-58.	1.4	5
300	Integration of radiation and immunotherapy in breast cancer - Treatment implications. <i>Breast</i> , 2018, 38, 66-74.	0.9	38
301	Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ. <i>BMC Cancer</i> , 2018, 18, 129.	1.1	40
302	Post-operative unadjuvanted therapeutic xenovaccination with chicken whole embryo vaccine suppresses distant micrometastases and prolongs survival in a murine Lewis lung carcinoma model. <i>Oncology Letters</i> , 2018, 15, 5098-5104.	0.8	1
303	The role of programmed death ligand-1 and tumor-infiltrating lymphocytes in breast cancer overexpressing HER2 gene. <i>Breast Cancer Research and Treatment</i> , 2018, 170, 293-302.	1.1	16

#	ARTICLE	IF	CITATIONS
304	High numbers of PDCD1 (PD-1)-positive T cells and <i>B2M</i> mutations in microsatellite-unstable colorectal cancer. <i>Oncolimmunology</i> , 2018, 7, e1390640.	2.1	48
305	Considerations for successful cancer immunotherapy in aged hosts. <i>Experimental Gerontology</i> , 2018, 107, 27-36.	1.2	33
306	Impact of Chronic Obstructive Pulmonary Disease on Immune-based Treatment for Lung Cancer. Moving toward Disease Interception. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 278-280.	2.5	5
307	CD4 and CD8 T lymphocyte interplay in controlling tumor growth. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 689-713.	2.4	351
308	Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies. <i>Journal of Thoracic Oncology</i> , 2018, 13, 16-26.	0.5	72
309	Immunochemotherapy mediated by thermosponge nanoparticles for synergistic anti-tumor effects. <i>Journal of Controlled Release</i> , 2018, 269, 322-336.	4.8	50
310	Overcoming Immune Suppression in the Tumor Microenvironment: Implications for Multi-modal Therapy. , 2018, , 13-38.		0
311	Emerging trends in the immunotherapy of pancreatic cancer. <i>Cancer Letters</i> , 2018, 417, 35-46.	3.2	77
312	Immunotherapeutic Biomarkers and Selection Strategies. <i>Current Cancer Research</i> , 2018, , 69-114.	0.2	0
314	Combinations of Genomically and Immune-Targeted Therapies in Early-Phase Clinical Trials. <i>Current Cancer Research</i> , 2018, , 243-280.	0.2	0
315	Influence of estrogen in non-small cell lung cancer and its clinical implications. <i>Journal of Thoracic Disease</i> , 2018, 10, 482-497.	0.6	74
316	The evolving understanding of immunoediting and the clinical impact of immune escape. <i>Journal of Thoracic Disease</i> , 2018, 10, 1248-1252.	0.6	10
317	Is there a room for immune checkpoint inhibitors in early stage non-small cell lung cancer?. <i>Journal of Thoracic Disease</i> , 2018, 10, S1427-S1437.	0.6	11
318	Predictive Value of CD3, CD8, CD45RO Expression in Stage II/III Colorectal Cancer. <i>International Journal of Reliable and Quality E-Healthcare</i> , 2018, 7, 18-36.	1.0	0
319	Dendritic Cells: The Tools for Cancer Treatment. , 0, , .		4
320	The role of neoantigen in immune checkpoint blockade therapy. <i>Experimental Hematology and Oncology</i> , 2018, 7, 28.	2.0	99
321	The immune system profoundly restricts intratumor genetic heterogeneity. <i>Science Immunology</i> , 2018, 3, .	5.6	83
322	Link between tumor-promoting fibrous microenvironment and an immunosuppressive microenvironment in stage I lung adenocarcinoma. <i>Lung Cancer</i> , 2018, 126, 64-71.	0.9	39

#	ARTICLE	IF	CITATIONS
323	Perspectives for cancer immunotherapy mediated by p19Arf plus interferon-beta gene transfer. <i>Clinics</i> , 2018, 73, e479s.	0.6	7
324	WW-Domain Containing Protein Roles in Breast Tumorigenesis. <i>Frontiers in Oncology</i> , 2018, 8, 580.	1.3	8
325	Immunodivergence in Metastatic Colorectal Cancer. <i>Cancer Cell</i> , 2018, 34, 876-878.	7.7	25
326	Adoptive T Cell Therapy: New Avenues Leading to Safe Targets and Powerful Allies. <i>Trends in Immunology</i> , 2018, 39, 921-936.	2.9	35
327	Turn Back the TIME: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression. <i>Frontiers in Immunology</i> , 2018, 9, 1977.	2.2	123
328	Is adaptive therapy natural?. <i>PLoS Biology</i> , 2018, 16, e2007066.	2.6	23
329	Integrative genomic analysis of mouse and human hepatocellular carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E9879-E9888.	3.3	67
330	Biomaterials for vaccine-based cancer immunotherapy. <i>Journal of Controlled Release</i> , 2018, 292, 256-276.	4.8	146
331	Combined Effect of IL-12R $\beta$ 2 and IL-23R Expression on Prognosis of Patients with Laryngeal Cancer. <i>Cellular Physiology and Biochemistry</i> , 2018, 50, 1041-1054.	1.1	10
332	Empowering dendritic cell cancer vaccination: the role of combinatorial strategies. <i>Cytotherapy</i> , 2018, 20, 1309-1323.	0.3	16
333	Predicting the response to neoadjuvant therapy for early-stage breast cancer: tumor-, blood-, and imaging-related biomarkers. <i>Cancer Management and Research</i> , 2018, Volume 10, 4333-4347.	0.9	37
334	Adoptive cell transfer: new perspective treatment in veterinary oncology. <i>Acta Veterinaria Scandinavica</i> , 2018, 60, 60.	0.5	11
335	Lymphoid environment in molecular subtypes of breast cancer. <i>Polish Journal of Pathology</i> , 2018, 69, 169-181.	0.1	4
336	Interleukin-1 $\beta$ as an intracellular alarmin in cancer biology. <i>Seminars in Immunology</i> , 2018, 38, 3-14.	2.7	26
337	Immunoengineering through cancer vaccines – A personalized and multi-step vaccine approach towards precise cancer immunity. <i>Journal of Controlled Release</i> , 2018, 289, 125-145.	4.8	31
338	The Interplay between Circulating Tumor Cells and the Immune System: From Immune Escape to Cancer Immunotherapy. <i>Diagnostics</i> , 2018, 8, 59.	1.3	57
339	CD8+ and CD163+ infiltrating cells and PD-L1 immunoexpression in oral leukoplakia and oral carcinoma. <i>Apmis</i> , 2018, 126, 732-738.	0.9	36
340	Prognostic significance of programmed death ligand-1 immunohistochemical expression in esophageal cancer. <i>Medicine (United States)</i> , 2018, 97, e11614.	0.4	14

#	ARTICLE	IF	CITATIONS
341	Nanoparticle Conjugation of Human Papillomavirus 16 E7-long Peptides Enhances Therapeutic Vaccine Efficacy against Solid Tumors in Mice. <i>Cancer Immunology Research</i> , 2018, 6, 1301-1313.	1.6	27
342	Precision medicine in cholangiocarcinoma. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 40-40.	1.5	61
343	Hot Spot and Whole-Tumor Enumeration of CD8+ Tumor-Infiltrating Lymphocytes Utilizing Digital Image Analysis Is Prognostic in Triple-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, 451-458.e1.	1.1	25
344	The role of the common gamma-chain family cytokines in $\hat{I}^3\hat{I}$ T cell-based anti-cancer immunotherapy. <i>Cytokine and Growth Factor Reviews</i> , 2018, 41, 54-64.	3.2	16
345	Leveraging Epigenetics to Enhance the Cellular Response to Chemotherapies and Improve Tumor Immunogenicity. <i>Advances in Cancer Research</i> , 2018, 138, 1-39.	1.9	1
346	Immunotherapie â€œ Die neue Ã„ra in der Onkologie. <i>Laryngo- Rhino- Otologie</i> , 2018, 97, S3-S47.	0.2	1
347	The Immune Biology of Microsatellite Unstable Cancer. , 2018, , 367-384.		4
348	Levels of peripheral blood polymorphonuclear myeloid-derived suppressor cells and selected cytokines are potentially prognostic of disease progression for patients with non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1393-1406.	2.0	37
349	Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 657-670.	3.3	14
350	Immunotherapy for pancreatic cancer: Barriers and breakthroughs. <i>Annals of Gastroenterological Surgery</i> , 2018, 2, 274-281.	1.2	119
351	Immune Escape Mechanisms and Future Prospects for Immunotherapy in Neuroblastoma. <i>BioMed Research International</i> , 2018, 2018, 1-11.	0.9	60
352	Proton irradiation orchestrates macrophage reprogramming through NF $\hat{I}$ B signaling. <i>Cell Death and Disease</i> , 2018, 9, 728.	2.7	58
353	Exploring the links between cancer and placenta development. <i>Open Biology</i> , 2018, 8, .	1.5	109
354	Immunotherapies: Exploiting the Immune System for Cancer Treatment. <i>Journal of Immunology Research</i> , 2018, 2018, 1-16.	0.9	89
355	Combined VLA-4â€œTargeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1843-1849.	2.8	52
356	Valproic acid as an adjunctive therapeutic agent for the treatment of breast cancer. <i>European Journal of Pharmacology</i> , 2018, 835, 61-74.	1.7	70
357	Neutrophil to Lymphocyte Ratio as Predictor of Treatment Response in Esophageal Squamous Cell Cancer. <i>Annals of Thoracic Surgery</i> , 2018, 106, 864-871.	0.7	26
358	Current status and future directions of cancer immunotherapy. <i>Journal of Cancer</i> , 2018, 9, 1773-1781.	1.2	273

#	ARTICLE	IF	CITATIONS
359	Antitumor Activity of Extract From the Sporoderm-Breaking Spore of <i>Ganoderma lucidum</i> : Restoration on Exhausted Cytotoxic T Cell With Gut Microbiota Remodeling. <i>Frontiers in Immunology</i> , 2018, 9, 1765.	2.2	70
360	Obesity and type-2 diabetes as inducers of premature cellular senescence and ageing. <i>Biogerontology</i> , 2018, 19, 447-459.	2.0	119
361	Origin and Consequences of Necroinflammation. <i>Physiological Reviews</i> , 2018, 98, 727-780.	13.1	147
362	The Tumor Microenvironment of Epithelial Ovarian Cancer and Its Influence on Response to Immunotherapy. <i>Cancers</i> , 2018, 10, 242.	1.7	97
363	Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas. <i>Frontiers in Immunology</i> , 2017, 8, 1899.	2.2	18
364	MHC Intratumoral Heterogeneity May Predict Cancer Progression and Response to Immunotherapy. <i>Frontiers in Immunology</i> , 2018, 9, 102.	2.2	25
365	Non-Cell Autonomous Effects of the Senescence-Associated Secretory Phenotype in Cancer Therapy. <i>Frontiers in Oncology</i> , 2018, 8, 164.	1.3	61
366	Immunotherapeutic interventions of Triple Negative Breast Cancer. <i>Journal of Translational Medicine</i> , 2018, 16, 147.	1.8	100
367	MiRNAs at the Crossroads between Innate Immunity and Cancer: Focus on Macrophages. <i>Cells</i> , 2018, 7, 12.	1.8	38
368	Advances in oncolytic adenovirus therapy for pancreatic cancer. <i>Cancer Letters</i> , 2018, 434, 56-69.	3.2	33
369	Regulation of Programmed Death Ligand 1 (PD-L1) Expression in Breast Cancer Cell Lines In Vitro and in Immunodeficient and Humanized Tumor Mice. <i>International Journal of Molecular Sciences</i> , 2018, 19, 563.	1.8	44
370	A Developed NK-92MI Cell Line with Siglec-7neg Phenotype Exhibits High and Sustainable Cytotoxicity against Leukemia Cells. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1073.	1.8	13
371	Cell-Based Immunotherapy of Gliomas. <i>Progress in Neurological Surgery</i> , 2018, 32, 90-100.	1.3	7
372	Antitumor and immunomodulatory activities of total flavonoids extract from persimmon leaves in H22 liver tumor-bearing mice. <i>Scientific Reports</i> , 2018, 8, 10523.	1.6	22
373	Extracellular ATP and P2 purinergic signalling in the tumour microenvironment. <i>Nature Reviews Cancer</i> , 2018, 18, 601-618.	12.8	491
374	New Insights Into the Role of Tissue Eosinophils in the Progression of Colorectal Cancer: A Literature Review. <i>Acta Medica Portuguesa</i> , 2018, 31, 329-337.	0.2	17
375	Aging Mouse Models Reveal Complex Tumor-Microenvironment Interactions in Cancer Progression. <i>Frontiers in Cell and Developmental Biology</i> , 2018, 6, 35.	1.8	5
376	Monitoring the responsiveness of T and antigen presenting cell compartments in breast cancer patients is useful to predict clinical tumor response to neoadjuvant chemotherapy. <i>BMC Cancer</i> , 2018, 18, 77.	1.1	10

#	ARTICLE	IF	CITATIONS
377	Immune checkpoint blockade for the treatment of human hepatocellular carcinoma. <i>Hepatology Research</i> , 2018, 48, 622-634.	1.8	58
378	Cancer-Targeted Oncolytic Adenoviruses for Modulation of the Immune System. <i>Current Cancer Drug Targets</i> , 2018, 18, 124-138.	0.8	13
379	Molecular Pathogenesis of Gastric Adenocarcinoma. , 2018, , .		0
380	Role of tumor microenvironment in the pathobiology of ovarian cancer: Insights and therapeutic opportunities. <i>Cancer Medicine</i> , 2018, 7, 5047-5056.	1.3	44
381	A cancer vaccine approach for personalized treatment of Lynch Syndrome. <i>Scientific Reports</i> , 2018, 8, 12122.	1.6	25
382	Spontaneous Regression of a Low-Grade Renal Cell Carcinoma With Oncocytic Features After Renal Mass Biopsy. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e1083-e1085.	0.9	6
383	Upregulation of PD-L1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300-mediated NF- $\kappa$ B signaling. <i>International Journal of Oncology</i> , 2018, 53, 1469-1480.	1.4	63
384	Immune checkpoints indoleamine 2,3-dioxygenase 1 and programmed death-ligand 1 in oral mucosal dysplasia. <i>Journal of Oral Pathology and Medicine</i> , 2018, 47, 773-780.	1.4	9
385	Current Immunotherapy of Melanoma. , 2018, , 567-576.		0
386	Breast Cancer Immunotherapy: An Update. <i>Breast Cancer: Basic and Clinical Research</i> , 2018, 12, 117822341877480.	0.6	37
387	Immunomodulation and cancer: Using mechanistic paradigms to inform risk assessment. <i>Current Opinion in Toxicology</i> , 2018, 10, 98-110.	2.6	3
388	Immunogenic effects of chemotherapy-induced tumor cell death. <i>Genes and Diseases</i> , 2018, 5, 194-203.	1.5	219
389	Exosomal lncRNAs and cancer: connecting the missing links. <i>Bioinformatics</i> , 2019, 35, 352-360.	1.8	51
390	Immune tumor board: integral part in the multidisciplinary management of cancer patients treated with cancer immunotherapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 485-495.	1.4	3
391	Molecular Alterations and Heterogeneity in Hepatocellular Carcinoma. <i>Molecular and Translational Medicine</i> , 2019, , 293-316.	0.4	4
392	The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatment—Review. <i>Frontiers in Immunology</i> , 2019, 10, 2043.	2.2	7
393	Tumor-associated macrophages affect the biological behavior of lung adenocarcinoma A549 cells through the PI3K/AKT signaling pathway. <i>Oncology Letters</i> , 2019, 18, 1840-1846.	0.8	19
394	The estrogen pathway as a modulator of response to immunotherapy. <i>Immunotherapy</i> , 2019, 11, 1161-1176.	1.0	7

#	ARTICLE	IF	CITATIONS
396	Therapeutic targeting of Notch signaling and immune checkpoint blockade in a spontaneous, genetically-heterogeneous mouse model of T-cell acute lymphoblastic leukemia. <i>DMM Disease Models and Mechanisms</i> , 2019, 12, .	1.2	8
397	Papillomavirus Immune Evasion Strategies Target the Infected Cell and the Local Immune System. <i>Frontiers in Oncology</i> , 2019, 9, 682.	1.3	128
398	Bioresponsive Protein Complex of aPD1 and aCD47 Antibodies for Enhanced Immunotherapy. <i>Nano Letters</i> , 2019, 19, 4879-4889.	4.5	103
399	Immune response profile of primary tumour, sentinel and non-sentinel axillary lymph nodes related to metastasis in breast cancer: an immunohistochemical point of view. <i>Histochemistry and Cell Biology</i> , 2019, 152, 177-193.	0.8	13
400	Cellular Therapy for Melanoma. , 2019, , 1-33.		0
401	Sleeping Beauty Mouse Models of Cancer: Microenvironmental Influences on Cancer Genetics. <i>Frontiers in Oncology</i> , 2019, 9, 611.	1.3	5
402	Novel and emerging therapies for B cell lymphoma. <i>Journal of Hematology and Oncology</i> , 2019, 12, 82.	6.9	37
403	Cancer Immunoediting and Hijacking of the Immune System. <i>Learning Materials in Biosciences</i> , 2019, , 117-139.	0.2	0
404	Signal Transduction in Radiation Oncology. , 2019, , 1-17.		0
405	The MHC class II-LIRB1 signalling axis as a promising target in cancer therapy. <i>Scandinavian Journal of Immunology</i> , 2019, 90, e12804.	1.3	34
406	Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle. <i>Cancer Biology and Medicine</i> , 2019, 16, 205.	1.4	40
407	Tumor-derived extracellular vesicles: molecular parcels that enable regulation of the immune response in cancer. <i>Journal of Cell Science</i> , 2019, 132, .	1.2	52
408	&lt;p&gt;Infiltrating CD4 and CD8 lymphocytes in HPV infected uterine cervical milieu&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 7647-7655.	0.9	28
409	Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 962.	1.6	29
410	The emergence of drug resistance to targeted cancer therapies: Clinical evidence. <i>Drug Resistance Updates</i> , 2019, 47, 100646.	6.5	81
411	A multiscale signalling network map of innate immune response in cancer reveals cell heterogeneity signatures. <i>Nature Communications</i> , 2019, 10, 4808.	5.8	44
412	Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients. <i>Journal of Translational Medicine</i> , 2019, 17, 355.	1.8	150
413	The Vexing Problem of Small Pulmonary Nodules. <i>Heart Lung and Circulation</i> , 2019, 28, 1612-1613.	0.2	0

#	ARTICLE	IF	CITATIONS
414	Retinoid X receptor agonist LG100268 modulates the immune microenvironment in preclinical breast cancer models. <i>Npj Breast Cancer</i> , 2019, 5, 39.	2.3	16
415	Targeting Immune-Related Biological Processes in Solid Tumors: We do Need Biomarkers. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5452.	1.8	53
416	Immunotherapy in the management of squamous cell carcinoma of the head and neck. <i>British Journal of Oral and Maxillofacial Surgery</i> , 2019, 57, 957-966.	0.4	4
417	Changes in total lymphocyte count and neutrophil-to-lymphocyte ratio after curative pancreatectomy in patients with pancreas adenocarcinoma and their prognostic role. <i>Journal of Surgical Oncology</i> , 2019, 120, 1102-1111.	0.8	14
418	Hepatic Tumor Microenvironments and Effects on NK Cell Phenotype and Function. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4131.	1.8	65
419	An optimized retinoic acid-inducible gene I agonist M8 induces immunogenic cell death markers in human cancer cells and dendritic cell activation. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1479-1492.	2.0	22
420	RNases Disrupt the Adaptive Potential of Malignant Cells: Perspectives for Therapy. <i>Frontiers in Pharmacology</i> , 2019, 10, 922.	1.6	3
421	Tumor neoantigens: from basic research to clinical applications. <i>Journal of Hematology and Oncology</i> , 2019, 12, 93.	6.9	266
422	Toward in silico Identification of Tumor Neoantigens in Immunotherapy. <i>Trends in Molecular Medicine</i> , 2019, 25, 980-992.	3.5	36
423	&lt;p&gt;The relevance between the immune response-related gene module and clinical traits in head and neck squamous cell carcinoma&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 7455-7472.	0.9	37
424	The Immune Microenvironment of Breast Cancer Progression. <i>Cancers</i> , 2019, 11, 1375.	1.7	68
425	Have Cells Harboring the HIV Reservoir Been Immunoedited?. <i>Frontiers in Immunology</i> , 2019, 10, 1842.	2.2	17
427	Role of evaluating tumorâ€infiltrating lymphocytes, programmed deathâ€1 ligand 1 and mismatch repair proteins expression in malignant mesothelioma. <i>International Journal of Oncology</i> , 2019, 55, 1157-1164.	1.4	13
428	Frequent Loss of IRF2 in Cancers Leads to Immune Evasion through Decreased MHC Class I Antigen Presentation and Increased PD-L1 Expression. <i>Journal of Immunology</i> , 2019, 203, 1999-2010.	0.4	63
429	Understanding mechanisms of primary resistance to checkpoint inhibitors will lead to precision immunotherapy of advanced gastric cancer. <i>Annals of Oncology</i> , 2019, 30, 351-352.	0.6	3
430	Amino acid residues involved in the heparin-binding activity of murine IL-12 in the context of an antibody-cytokine fusion protein. <i>Cytokine</i> , 2019, 120, 220-226.	1.4	4
431	Targeting Immune-Mediated Dormancy: A Promising Treatment of Cancer. <i>Frontiers in Oncology</i> , 2019, 9, 498.	1.3	33
432	â€T cells: pleiotropic immune effectors with therapeutic potential in cancer. <i>Nature Reviews Cancer</i> , 2019, 19, 392-404.	12.8	255



#	ARTICLE	IF	CITATIONS
433	Epidemiologic perspectives on immunosuppressed populations and the immunosurveillance and immunocontainment of cancer. <i>American Journal of Transplantation</i> , 2019, 19, 3223-3232.	2.6	31
434	Cell Fusion in Malignancy: A Cause or Consequence? A Provocateur or Cure?. <i>Cells</i> , 2019, 8, 587.	1.8	15
435	Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2019, 10, 1078.	2.2	430
436	Multifaceted Role of the Placental Growth Factor (PlGF) in the Antitumor Immune Response and Cancer Progression. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2970.	1.8	53
437	Molecular and Cell Biology of Cancer. <i>Learning Materials in Biosciences</i> , 2019, , .	0.2	3
438	The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous Premalignancy. <i>Cancer Research</i> , 2019, 79, 5022-5033.	0.4	37
439	Prognostic value of B cells in cutaneous melanoma. <i>Genome Medicine</i> , 2019, 11, 36.	3.6	81
440	A mathematical model of viral oncology as an immuno-oncology instigator. <i>Mathematical Medicine and Biology</i> , 2020, 37, 117-151.	0.8	9
441	Immunomodulation and Immunotherapy for Gastric Cancer. <i>Current Clinical Pathology</i> , 2019, , 189-212.	0.0	1
442	The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 475, 13-23.	1.4	27
443	The biology and clinical potential of circulating tumor cells. <i>Radiology and Oncology</i> , 2019, 53, 131-147.	0.6	53
444	Integrated cancer tissue engineering models for precision medicine. <i>PLoS ONE</i> , 2019, 14, e0216564.	1.1	57
445	Constitutive Expression of NRAS with Q61R Driver Mutation Activates Processes of Epithelialâ€“Mesenchymal Transition and Leads to Substantial Transcriptome Change of Nthy-ori 3â€“1 Thyroid Epithelial Cells. <i>Biochemistry (Moscow)</i> , 2019, 84, 416-425.	0.7	4
446	Targeted delivery of ibrutinib to tumor-associated macrophages by sialic acid-stearic acid conjugate modified nanocomplexes for cancer immunotherapy. <i>Acta Biomaterialia</i> , 2019, 92, 184-195.	4.1	69
447	Understanding the mechanisms of immune-evasion by lung cancer in the context of chronic inflammation in emphysema. <i>Journal of Thoracic Disease</i> , 2019, 11, 382-385.	0.6	2
448	Gastric Cancer In The Precision Medicine Era. <i>Current Clinical Pathology</i> , 2019, , .	0.0	2
449	Immunotherapeutics in Multiple Myeloma: How Can Translational Mouse Models Help?. <i>Journal of Oncology</i> , 2019, 2019, 1-18.	0.6	5
450	The Role of the Immune System in Cutaneous Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2009.	1.8	81

#	ARTICLE	IF	CITATIONS
451	Positive Immuno-Modulation Following Radiofrequency Assisted Liver Resection in Hepatocellular Carcinoma. <i>Journal of Clinical Medicine</i> , 2019, 8, 385.	1.0	21
452	TISIDB: an integrated repository portal for tumor-immune system interactions. <i>Bioinformatics</i> , 2019, 35, 4200-4202.	1.8	1,281
453	From Basic to Clinical Immunology. , 2019, , .		5
454	Primary Immunodeficiency and Cancer Predisposition Revisited: Embedding Two Closely Related Concepts Into an Integrative Conceptual Framework. <i>Frontiers in Immunology</i> , 2018, 9, 3136.	2.2	47
455	Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. <i>Nature Medicine</i> , 2019, 25, 656-666.	15.2	461
456	Tumor infiltrating lymphocytes: The regulator of melanoma evolution (Review). <i>Oncology Letters</i> , 2019, 17, 4155-4161.	0.8	66
457	Targeting immune cells for cancer therapy. <i>Redox Biology</i> , 2019, 25, 101174.	3.9	151
458	Interactions between cancer stem cells, immune system and some environmental components: Friends or foes?. <i>Immunology Letters</i> , 2019, 208, 19-29.	1.1	66
459	Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response. <i>Journal of Physical Education and Sports Management</i> , 2019, 5, a003566.	0.5	6
460	Immunotherapy for Head and Neck Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2019, 33, 301-321.	0.9	19
461	Tissue-resident memory T cells keep cancer dormant. <i>Cell Research</i> , 2019, 29, 341-342.	5.7	6
462	Tailoring Nanomaterials for Targeting Tumor-Associated Macrophages. <i>Advanced Materials</i> , 2019, 31, e1808303.	11.1	223
463	Progesterone Receptor Attenuates STAT1-Mediated IFN Signaling in Breast Cancer. <i>Journal of Immunology</i> , 2019, 202, 3076-3086.	0.4	29
464	Natural killer cells limit the clearance of senescent lung adenocarcinoma cells. <i>Oncogenesis</i> , 2019, 8, 24.	2.1	14
465	First-in-class ruthenium anticancer drug (KP1339/IT-139) induces an immunogenic cell death signature in colorectal spheroids <i>in vitro</i> . <i>Metallomics</i> , 2019, 11, 1044-1048.	1.0	92
466	Immunotherapy of Cancer: Developments and Reference Points, an Unorthodox Approach. <i>Integrative Cancer Therapies</i> , 2019, 18, 153473541982709.	0.8	2
467	Immunotherapeutic advances in gastrointestinal malignancies. <i>Npj Precision Oncology</i> , 2019, 3, 4.	2.3	16
468	Prognostic value of CD8+PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer. , 2019, 7, 34.		75

#	ARTICLE	IF	CITATIONS
469	Tumor-associated macrophages: a short compendium. Cellular and Molecular Life Sciences, 2019, 76, 1447-1458.	2.4	71
470	Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. Trends in Cell Biology, 2019, 29, 396-416.	3.6	66
471	The second genome: Effects of the mitochondrial genome on cancer progression. Advances in Cancer Research, 2019, 142, 63-105.	1.9	19
472	Immunotherapy and targeted therapy combinations in metastatic breast cancer. Lancet Oncology, The, 2019, 20, e175-e186.	5.1	329
473	Mathematical modeling of tumor-immune cell interactions. Journal of Theoretical Biology, 2019, 469, 47-60.	0.8	95
474	Immune Checkpoint Inhibitors and Beyond: An Overview of Immune-Based Therapies in Merkel Cell Carcinoma. American Journal of Clinical Dermatology, 2019, 20, 391-407.	3.3	35
475	Anti-tumor immunity induced by ectopic expression of viral antigens is transient and limited by immune escape. Oncoimmunology, 2019, 8, e1568809.	2.1	22
476	Cancer Vaccines. , 2019, , .		1
477	Selenium and selenoproteins in prostanoid metabolism and immunity. Critical Reviews in Biochemistry and Molecular Biology, 2019, 54, 484-516.	2.3	51
478	Is Neuronal Histamine Signaling Involved in Cancer Cachexia? Implications and Perspectives. Frontiers in Oncology, 2019, 9, 1409.	1.3	8
479	Mononuclear but Not Polymorphonuclear Phagocyte Depletion Increases Circulation Times and Improves Mammary Tumor-Homing Efficiency of Donor Bone Marrow-Derived Monocytes. Cancers, 2019, 11, 1752.	1.7	5
480	Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications. Frontiers in Immunology, 2019, 10, 2393.	2.2	92
481	Therapeutic vaccines for advanced non-small cell lung cancer. The Cochrane Library, 2019, , .	1.5	6
482	Tumor PD-L1 Induction by Resveratrol/Piceatannol May Function as a Search, Enhance, and Engage (â€œSEEâ€) Signal to Facilitate the Elimination of â€œCold, Non-Responsiveâ€ Low PD-L1-Expressing Tumors by PD-L1 Blockade. International Journal of Molecular Sciences, 2019, 20, 5969.	1.8	9
483	Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells. Frontiers in Oncology, 2019, 9, 1148.	1.3	90
484	Bioactive Compounds: Natural Defense Against Cancer?. Biomolecules, 2019, 9, 758.	1.8	98
485	Escape From ALL-CARTaz. Cancer Journal (Sudbury, Mass ), 2019, 25, 217-222.	1.0	20
486	Mechanisms of failure of chimeric antigen receptor T-cell therapy. Current Opinion in Hematology, 2019, 26, 427-433.	1.2	30

#	ARTICLE	IF	CITATIONS
487	An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2019, 34, 147-159.	0.7	20
488	Functional Nanomaterials Optimized to Circumvent Tumor Immunological Tolerance. <i>Advanced Functional Materials</i> , 2019, 29, 1806087.	7.8	21
489	Immuno-Oncology in Lung Cancer. , 2019, , 487-497.		1
490	Immunotherapy for Head and Neck Cancer. <i>Oral and Maxillofacial Surgery Clinics of North America</i> , 2019, 31, 85-100.	0.4	36
491	Doxorubicin-induced cardiotoxicity involves IFN $\gamma$ -mediated metabolic reprogramming in cardiomyocytes. <i>Journal of Pathology</i> , 2019, 247, 320-332.	2.1	36
492	Signal interaction between the tumour and inflammatory cells in patients with gastrointestinal cancer: Implications for treatment. <i>Cellular Signalling</i> , 2019, 54, 81-90.	1.7	11
493	A CD40 Agonist and PD-1 Antagonist Antibody Reprogram the Microenvironment of Nonimmunogenic Tumors to Allow T-cell-mediated Anticancer Activity. <i>Cancer Immunology Research</i> , 2019, 7, 428-442.	1.6	92
494	Elevated pre-existing lymphocytic infiltrates in tumour stroma predict poor prognosis in resectable urothelial carcinoma of the bladder. <i>Histopathology</i> , 2019, 75, 354-364.	1.6	4
495	Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: a systematic review and meta-analysis. <i>World Journal of Surgical Oncology</i> , 2019, 17, 4.	0.8	43
496	Evaluation of tumor-infiltrating lymphocytes and association with prognosis in <i>BRCA</i> -mutated breast cancer. <i>Acta Oncologica</i> , 2019, 58, 363-370.	0.8	22
497	FoxP3 and IDO in Canine Melanocytic Tumors. <i>Veterinary Pathology</i> , 2019, 56, 189-199.	0.8	23
498	<i>Cancer Immunology</i> . , 2019, , 1-17.		4
499	The prognostic value of immune checkpoints in oral squamous cell carcinoma. <i>Oral Diseases</i> , 2019, 25, 1435-1445.	1.5	33
500	Composition and Clinical Impact of the Immunologic Tumor Microenvironment in Oral Squamous Cell Carcinoma. <i>Journal of Immunology</i> , 2019, 202, 278-291.	0.4	61
501	What, Why, Where, and When: Bringing Timing to Immuno-Oncology. <i>Trends in Immunology</i> , 2019, 40, 12-21.	2.9	50
502	Rational combination immunotherapeutic approaches for effective cancer treatment. <i>Journal of Controlled Release</i> , 2019, 294, 114-130.	4.8	28
503	Glioblastoma Therapy in the Age of Molecular Medicine. <i>Trends in Cancer</i> , 2019, 5, 46-65.	3.8	68
504	Cancer immunoediting and resistance to T cell-based immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 151-167.	12.5	1,093

#	ARTICLE	IF	CITATIONS
505	Metal Drugs and the Anticancer Immune Response. <i>Chemical Reviews</i> , 2019, 119, 1519-1624.	23.0	237
506	Cancer Immunosurveillance by T Cells. <i>International Review of Cell and Molecular Biology</i> , 2019, 342, 149-173.	1.6	45
507	Progression from low- to high-grade in a glioblastoma model reveals the pivotal role of immunoediting. <i>Cancer Letters</i> , 2019, 442, 213-221.	3.2	18
508	Reasoning the effect of immunotherapy after chemoradiation in the PACIFIC trial. <i>Future Oncology</i> , 2019, 15, 81-94.	1.1	2
509	TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class II low cancers. <i>Molecular Immunology</i> , 2019, 113, 43-49.	1.0	36
510	The Relationship Between Tumor-Infiltrating Lymphocytes, PD-L1 Expression, Driver Mutations and Clinical Outcome Parameters in Non-Small Cell Lung Cancer Adenocarcinoma in Patients with a Limited to no Smoking History. <i>Pathology and Oncology Research</i> , 2020, 26, 1221-1228.	0.9	5
511	Analysis of the immune status from peripheral whole blood with a single-tube multicolor flow cytometry assay. <i>Methods in Enzymology</i> , 2020, 632, 389-415.	0.4	10
512	Toll-like receptor-induced cytokines as immunotherapeutic targets in cancers and autoimmune diseases. <i>Seminars in Cancer Biology</i> , 2020, 64, 61-82.	4.3	59
513	Tracing the Equilibrium Phase of Cancer Immunoediting in Epidermal Neoplasms via Longitudinal Intravital Imaging. <i>Journal of Investigative Dermatology</i> , 2020, 140, 891-900.e10.	0.3	10
515	Dendritic cells in cancer immunology and immunotherapy. <i>Nature Reviews Immunology</i> , 2020, 20, 7-24.	10.6	1,401
516	Progression or suppression: Two sides of the innate lymphoid cells in cancer. <i>Journal of Cellular Biochemistry</i> , 2020, 121, 2739-2755.	1.2	6
517	Breast cancer stem cell antigens as targets for immunotherapy. <i>Seminars in Immunology</i> , 2020, 47, 101386.	2.7	48
518	SOX9: The master regulator of cell fate in breast cancer. <i>Biochemical Pharmacology</i> , 2020, 174, 113789.	2.0	47
519	Aggressive Mammary Cancers Lacking Lymphocytic Infiltration Arise in Irradiated Mice and Can Be Prevented by Dietary Intervention. <i>Cancer Immunology Research</i> , 2020, 8, 217-229.	1.6	11
520	Immunoregulatory Potential of Exosomes Derived from Cancer Stem Cells. <i>Stem Cells and Development</i> , 2020, 29, 327-335.	1.1	11
521	Microbe-MUC1 Crosstalk in Cancer-Associated Infections. <i>Trends in Molecular Medicine</i> , 2020, 26, 324-336.	3.5	24
522	Construction of a core-shell microneedle system to achieve targeted co-delivery of checkpoint inhibitors for melanoma immunotherapy. <i>Acta Biomaterialia</i> , 2020, 104, 147-157.	4.1	76
523	Targeting innate sensing in the tumor microenvironment to improve immunotherapy. <i>Cellular and Molecular Immunology</i> , 2020, 17, 13-26.	4.8	76

#	ARTICLE	IF	CITATIONS
524	Tumour evolution in hepatocellular carcinoma. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 139-152.	8.2	501
525	Tumour-infiltrating lymphocytes in canine melanocytic tumours: An investigation on the prognostic role of CD3 <sup>+</sup> and CD20 <sup>+</sup> lymphocytic populations. <i>Veterinary and Comparative Oncology</i> , 2020, 18, 370-380.	0.8	19
526	A cytofluorimetric assay to evaluate T cell polyfunctionality. <i>Methods in Enzymology</i> , 2020, 631, 61-76.	0.4	0
527	Advances of immune checkpoints in colorectal cancer treatment. <i>Biomedicine and Pharmacotherapy</i> , 2020, 123, 109745.	2.5	21
528	Sarcoma European and Latin American Network (SELNET) Recommendations on Prioritization in Sarcoma Care During the COVID-19 Pandemic. <i>Oncologist</i> , 2020, 25, e1562-e1573.	1.9	6
529	The impact of immunotherapy on the survival of pancreatic adenocarcinoma patients who do not receive definitive surgery of the tumor. <i>Clinical and Translational Radiation Oncology</i> , 2020, 24, 34-40.	0.9	11
530	Predictive molecular markers in the era of immunotherapy. <i>Journal of Pancreatology</i> , 2020, 3, 132-138.	0.3	5
531	Identification of a prognostic gene signature based on an immunogenomic landscape analysis of bladder cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2020, 24, 13370-13382.	1.6	23
532	Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant. <i>Frontiers in Immunology</i> , 2020, 11, 577869.	2.2	147
533	Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7032.	1.8	20
534	An immune risk score with potential implications in prognosis and immunotherapy of metastatic melanoma. <i>International Immunopharmacology</i> , 2020, 88, 106921.	1.7	5
535	Cancer progression and the invisible phase of metastatic colonization. <i>Nature Reviews Cancer</i> , 2020, 20, 681-694.	12.8	194
536	The transcription factor C/EBP $\beta$ orchestrates dendritic cell maturation and functionality under homeostatic and malignant conditions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 26328-26339.	3.3	13
537	Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion. <i>Cancers</i> , 2020, 12, 1872.	1.7	18
538	Targeting Stat3 signaling impairs the progression of bladder cancer in a mouse model. <i>Cancer Letters</i> , 2020, 490, 89-99.	3.2	21
539	Oral exposure to BDE-209 modulates metastatic spread of melanoma in C57BL/6 mice inoculated with B16-F10 cells. <i>Chemosphere</i> , 2020, 260, 127556.	4.2	7
540	Immunotherapy in the Treatment of Metastatic Melanoma: Current Knowledge and Future Directions. <i>Journal of Immunology Research</i> , 2020, 2020, 1-12.	0.9	127
541	Prognostic Role of Immune Markers in Triple Negative Breast Carcinoma. <i>Pathology and Oncology Research</i> , 2020, 26, 2733-2745.	0.9	14

#	ARTICLE	IF	CITATIONS
542	Ganglioside Biochemistry. , 2020, , .		6
543	Technical Advancements for Studying Immune Regulation of Disseminated Dormant Cancer Cells. <i>Frontiers in Oncology</i> , 2020, 10, 594514.	1.3	10
544	Applications of Single-Cell Omics to Dissect Tumor Microenvironment. <i>Frontiers in Genetics</i> , 2020, 11, 548719.	1.1	18
545	Shaping the Treatment Paradigm Based on the Current Understanding of the Pathobiology of Multiple Myeloma: An Overview. <i>Cancers</i> , 2020, 12, 3488.	1.7	6
546	Strategies for Cancer Immunotherapy Using Induced Pluripotency Stem Cells-Based Vaccines. <i>Cancers</i> , 2020, 12, 3581.	1.7	6
547	Lymphotropic Viruses: Chronic Inflammation and Induction of Cancers. <i>Biology</i> , 2020, 9, 390.	1.3	9
548	Non-Melanoma Skin Cancers: Biological and Clinical Features. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5394.	1.8	83
549	Characterization of the role of Samsn1 loss in multiple myeloma development. <i>FASEB BioAdvances</i> , 2020, 2, 554-572.	1.3	3
550	Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD~1/PD-L1 Checkpoint Blockade. <i>Cancers</i> , 2020, 12, 3048.	1.7	37
551	Resisting Resistance to Immune Checkpoint Therapy: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6176.	1.8	19
552	Lack of myeloid cell infiltration as an acquired resistance strategy to immunotherapy. , 2020, 8, e001326.		16
553	LINC00973 is involved in cancer immune suppression through positive regulation of Siglec~15 in clear~cell renal cell carcinoma. <i>Cancer Science</i> , 2020, 111, 3693-3704.	1.7	28
554	The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution. <i>Nature Communications</i> , 2020, 11, 4740.	5.8	78
555	Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition. <i>Trends in Immunology</i> , 2020, 41, 948-963.	2.9	41
556	Identification of microRNAs Targeting the Transporter Associated with Antigen Processing TAP1 in Melanoma. <i>Journal of Clinical Medicine</i> , 2020, 9, 2690.	1.0	18
557	The Synergistic Effect of an ATP-Competitive Inhibitor of mTOR and Metformin on Pancreatic Tumor Growth. <i>Current Developments in Nutrition</i> , 2020, 4, nzaa131.	0.1	6
558	Association of Immunotherapy With Survival Among Patients With Brain Metastases Whose Cancer Was Managed With Definitive Surgery of the Primary Tumor. <i>JAMA Network Open</i> , 2020, 3, e2015444.	2.8	33
559	High-Dimensional Characterization of the Systemic Immune Landscape Informs on Synergism Between Radiation Therapy and Immune Checkpoint Blockade. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 70-80.	0.4	3

#	ARTICLE	IF	CITATIONS
560	Tumor Infiltrating Lymphocytes in Pet Rabbit Mammary Carcinomas: A Study with Relevance to Comparative Pathology. <i>Animals</i> , 2020, 10, 1437.	1.0	3
561	Clinical Data on Immunotherapy in Breast Cancer. <i>Breast Care</i> , 2020, 15, 450-469.	0.8	12
562	The Role of Human $\beta$ 1 T Cells in Anti-Tumor Immunity and Their Potential for Cancer Immunotherapy. <i>Cells</i> , 2020, 9, 1206.	1.8	43
563	Galectins as Checkpoints of the Immune System in Cancers, Their Clinical Relevance, and Implication in Clinical Trials. <i>Biomolecules</i> , 2020, 10, 750.	1.8	38
564	P53: A Guardian of Immunity Becomes Its Saboteur through Mutation. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3452.	1.8	56
565	Deep-Learning-Based Characterization of Tumor-Infiltrating Lymphocytes in Breast Cancers From Histopathology Images and Multiomics Data. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 480-490.	1.0	52
566	Insights into the Molecular Mechanisms Behind Intralesional Immunotherapies for Advanced Melanoma. <i>Cancers</i> , 2020, 12, 1321.	1.7	11
567	Systemic modulation of stress and immune parameters in patients treated for prostate adenocarcinoma by intensity-modulated radiation therapy or stereotactic ablative body radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2020, 196, 1018-1033.	1.0	12
568	Prevalence of $\text{PD-L1}$ expression in head and neck squamous precancerous lesions: a systematic review and meta-analysis. <i>Head and Neck</i> , 2020, 42, 3018-3030.	0.9	23
569	Mechanisms of immune escape in the cancer immune cycle. <i>International Immunopharmacology</i> , 2020, 86, 106700.	1.7	85
570	Co-Regulation of Immune Checkpoint PD-L1 with Interferon-Gamma Signaling is Associated with a Survival Benefit in Renal Cell Cancer. <i>Targeted Oncology</i> , 2020, 15, 377-390.	1.7	15
571	Immunotherapy in Advanced Non-Small Cell Lung Cancer. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2020, 41, 400-408.	0.8	4
572	Obesity and the Impact on Cutaneous Melanoma: Friend or Foe?. <i>Cancers</i> , 2020, 12, 1583.	1.7	29
573	Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. <i>Molecular Cell</i> , 2020, 78, 1207-1223.e8.	4.5	43
574	Metabolism in tumor microenvironment: Implications for cancer immunotherapy. <i>MedComm</i> , 2020, 1, 47-68.	3.1	93
575	Decoding the Role of Interleukin-30 in the Crosstalk between Cancer and Myeloid Cells. <i>Cells</i> , 2020, 9, 615.	1.8	11
576	Designs of Antigen Structure and Composition for Improved Protein-Based Vaccine Efficacy. <i>Frontiers in Immunology</i> , 2020, 11, 283.	2.2	46
578	Immune-based therapies for hepatocellular carcinoma. <i>Oncogene</i> , 2020, 39, 3620-3637.	2.6	154



#	ARTICLE	IF	CITATIONS
579	Noncoding RNAs in cancer immunity: functions, regulatory mechanisms, and clinical application. <i>Molecular Cancer</i> , 2020, 19, 48.	7.9	64
580	(-)-Sativan Inhibits Tumor Development and Regulates miR-200c/PD-L1 in Triple Negative Breast Cancer Cells. <i>Frontiers in Pharmacology</i> , 2020, 11, 251.	1.6	46
581	Tracking Neoantigens by Personalized Circulating Tumor DNA Sequencing during Checkpoint Blockade Immunotherapy in Non-small Cell Lung Cancer. <i>Advanced Science</i> , 2020, 7, 1903410.	5.6	30
582	Programmed cell death ligand-1: A dynamic immune checkpoint in cancer therapy. <i>Chemical Biology and Drug Design</i> , 2020, 95, 552-566.	1.5	13
583	Characterizing the Dysfunctional NK Cell: Assessing the Clinical Relevance of Exhaustion, Anergy, and Senescence. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 49.	1.8	122
584	Endoplasmic Reticulum-Associated Degradation-Dependent Processing in Cross-Presentation and Its Potential for Dendritic Cell Vaccinations: A Review. <i>Pharmaceutics</i> , 2020, 12, 153.	2.0	4
585	Neoantigen prediction and computational perspectives towards clinical benefit: recommendations from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2020, 31, 978-990.	0.6	87
586	Keeping Patients With Cancer Exercising in the Age of COVID-19. <i>JCO Oncology Practice</i> , 2020, 16, 656-664.	1.4	55
587	Preclinical and Clinical Immunotherapeutic Strategies in Epithelial Ovarian Cancer. <i>Cancers</i> , 2020, 12, 1761.	1.7	8
588	Peripheral Blood Classical Monocytes and Plasma Interleukin 10 Are Associated to Neoadjuvant Chemotherapy Response in Breast Cancer Patients. <i>Frontiers in Immunology</i> , 2020, 11, 1413.	2.2	16
589	Increased both PD-L1 and PD-L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis. <i>Scientific Reports</i> , 2020, 10, 10377.	1.6	26
590	Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer. <i>Seminars in Cancer Biology</i> , 2022, 79, 44-57.	4.3	104
591	Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases. <i>Lung Cancer</i> , 2020, 142, 70-79.	0.9	17
592	Assessing Treatment Benefit in Immuno-oncology. <i>Statistics in Biosciences</i> , 2020, 12, 83-103.	0.6	10
593	The Biology of Lung Cancer. <i>Clinics in Chest Medicine</i> , 2020, 41, 25-38.	0.8	52
594	Cancer as a disease of old age: changing mutational and microenvironmental landscapes. <i>British Journal of Cancer</i> , 2020, 122, 943-952.	2.9	153
595	Down-regulation of the human major histocompatibility complex class I chain-related gene A (MICA) and its receptor is mediated by microRNA-146b-5p and is a potential mechanism of immunoeediting in papillary thyroid carcinoma. <i>Experimental and Molecular Pathology</i> , 2020, 113, 104379.	0.9	13
596	TYK2 in Tumor Immunosurveillance. <i>Cancers</i> , 2020, 12, 150.	1.7	18

#	ARTICLE	IF	CITATIONS
597	Cytokines as potential combination agents with PD-1/PD-L1 blockade for cancer treatment. <i>Journal of Cellular Physiology</i> , 2020, 235, 5449-5460.	2.0	42
598	Prediagnostic Immune Cell Profiles and Breast Cancer. <i>JAMA Network Open</i> , 2020, 3, e1919536.	2.8	25
599	Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response. <i>Journal of Clinical Medicine</i> , 2020, 9, 286.	1.0	50
600	Tumor Immunology and Tumor Evolution: Intertwined Histories. <i>Immunity</i> , 2020, 52, 55-81.	6.6	357
601	Progress and challenges of personalized neoantigens in the clinical treatment of tumors. <i>Medicine in Drug Discovery</i> , 2020, 6, 100030.	2.3	3
603	Unravelling the heterogeneity and dynamic relationships of tumor-infiltrating T cells by single-cell RNA sequencing analysis. <i>Journal of Leukocyte Biology</i> , 2020, 107, 917-932.	1.5	21
604	Hypoxanthine Guanine Phosphoribosyltransferase expression is negatively correlated with immune activity through its regulation of purine synthesis. <i>Immunobiology</i> , 2020, 225, 151931.	0.8	7
605	Targeted drug delivery therapies inspired by natural taxes. <i>Journal of Controlled Release</i> , 2020, 322, 439-456.	4.8	17
606	Contribution of Macrophages and T Cells in Skeletal Metastasis. <i>Cancers</i> , 2020, 12, 1014.	1.7	19
607	Establishment and Characterization of Humanized Mouse NPC-PDX Model for Testing Immunotherapy. <i>Cancers</i> , 2020, 12, 1025.	1.7	30
608	Breast cancer immunology and immunotherapy: targeting the programmed cell death protein-1/programmed cell death protein ligand-1. <i>Chinese Medical Journal</i> , 2020, 133, 853-862.	0.9	21
609	Biochemistry and metabolism of <i>Toxoplasma gondii</i> : purine and pyrimidine acquisition in <i>Toxoplasma gondii</i> and other Apicomplexa. , 2020, , 397-449.		7
610	Vaccination against Nonmutated Neoantigens Induced in Recurrent and Future Tumors. <i>Cancer Immunology Research</i> , 2020, 8, 856-868.	1.6	12
611	Heterogeneity Fair: Commentary to Menter and Tzankov "Lymphomas and Their Microenvironment: A Multifaceted Relationship". <i>Pathobiology</i> , 2020, 87, 155-158.	1.9	0
612	Platelet-Leukocyte Interplay in Cancer Development and Progression. <i>Cells</i> , 2020, 9, 855.	1.8	63
613	Tumor Targeted Nanocarriers for Immunotherapy. <i>Molecules</i> , 2020, 25, 1508.	1.7	26
614	Crosstalk between tumors at anatomically distinct sites. <i>FEBS Journal</i> , 2021, 288, 81-90.	2.2	9
615	Genomic profiling of sporadic liver metastatic colorectal cancer. <i>Seminars in Cancer Biology</i> , 2021, 71, 98-108.	4.3	8

#	ARTICLE	IF	CITATIONS
616	IL-23R in laryngeal cancer: a cancer immunoeediting process that facilitates tumor cell proliferation and results in cisplatin resistance. <i>Carcinogenesis</i> , 2021, 42, 118-126.	1.3	11
617	Distribution pattern of tumor infiltrating lymphocytes and tumor microenvironment composition as prognostic indicators in anorectal malignant melanoma. <i>Modern Pathology</i> , 2021, 34, 141-160.	2.9	9
618	Joining Forces: Improving Clinical Response to Cellular Immunotherapies with Small-Molecule Inhibitors. <i>Trends in Molecular Medicine</i> , 2021, 27, 75-90.	3.5	5
619	FoxP3, CTLA-4, and IDO in Canine Melanocytic Tumors. <i>Veterinary Pathology</i> , 2021, 58, 42-52.	0.8	15
620	Metabolism and immunity in breast cancer. <i>Frontiers of Medicine</i> , 2021, 15, 178-207.	1.5	27
621	Modeling and simulations of CoViD-19 molecular mechanism induced by cytokines storm during SARS-CoV2 infection. <i>Journal of Molecular Liquids</i> , 2021, 327, 114863.	2.3	50
622	Immune-related gene data-based molecular subtyping related to the prognosis of breast cancer patients. <i>Breast Cancer</i> , 2021, 28, 513-526.	1.3	1
623	The lingering mysteries of metastatic recurrence in breast cancer. <i>British Journal of Cancer</i> , 2021, 124, 13-26.	2.9	263
624	Pharmacological combination of nivolumab with dendritic cell vaccines in cancer immunotherapy: An overview. <i>Pharmacological Research</i> , 2021, 164, 105309.	3.1	12
625	Cell by cell immuno- and cancer marker profiling of non-small cell lung cancer tissue: Checkpoint marker expression on CD103+, CD4+ T-cells predicts circulating tumor cells. <i>Translational Oncology</i> , 2021, 14, 100953.	1.7	6
626	Surface receptor-mediated targeted drug delivery systems for enhanced cancer treatment: A state-of-the-art review. <i>Drug Development Research</i> , 2021, 82, 309-340.	1.4	42
627	Microneedles for painless transdermal immunotherapeutic applications. <i>Journal of Controlled Release</i> , 2021, 330, 185-217.	4.8	131
628	The new role for an old guy: MYC as an immunoplayer. <i>Journal of Cellular Physiology</i> , 2021, 236, 3234-3243.	2.0	8
629	Comprehensive Phenotyping of Dendritic Cells in Cancer Patients by Flow Cytometry. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2021, 99, 218-230.	1.1	6
630	Evaluation Challenges in the Validation of B7-H3 as Oral Tongue Cancer Prognosticator. <i>Head and Neck Pathology</i> , 2021, 15, 469-478.	1.3	1
631	Nanomedicines as Multifunctional Modulators of Melanoma Immune Microenvironment. <i>Advanced Therapeutics</i> , 2021, 4, 2000147.	1.6	2
632	A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy. <i>Nature Communications</i> , 2021, 12, 653.	5.8	48
633	Exploring the "Dormancy Activation Switch"™ in the Tumour Microenvironment for Metastatic Lung Cancer: The Possible Role of MicroRNA. , 2021, , 191-215.		0

#	ARTICLE	IF	CITATIONS
634	Response Rate and Survival at Key Timepoints With PD-1 Blockade vs Chemotherapy in PD-L1 Subgroups: Meta-Analysis of Metastatic NSCLC Trials. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab012.	1.4	16
635	Biohybrid Nanosystems for Cancer Treatment: Merging the Best of Two Worlds. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1295, 135-162.	0.8	0
636	Stromal Protein-Mediated Immune Regulation in Digestive Cancers. <i>Cancers</i> , 2021, 13, 146.	1.7	18
637	Exploring the clinical value of tumor microenvironment in platinum-resistant ovarian cancer. <i>Seminars in Cancer Biology</i> , 2021, 77, 83-98.	4.3	28
638	Complex Interaction Among Immune, Inflammatory, and Carcinogenic Mechanisms in the Head and Neck Squamous Cell Carcinoma. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1335, 11-35.	0.8	11
639	Biological bases of cancer immunotherapy. <i>Expert Reviews in Molecular Medicine</i> , 2021, 23, e3.	1.6	14
640	The role of dendritic cells in tumor microenvironments and their uses as therapeutic targets. <i>BMB Reports</i> , 2021, 54, 31-43.	1.1	33
641	Harnessing the Immune System Against Multiple Myeloma: Challenges and Opportunities. <i>Frontiers in Oncology</i> , 2020, 10, 606368.	1.3	23
642	Circular RNAs Interaction with MiRNAs: Emerging Roles in Breast Cancer. <i>International Journal of Medical Sciences</i> , 2021, 18, 3182-3196.	1.1	7
643	Targeted Cancer Therapy and Its Ophthalmic Side Effects: A Review. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 6-15.	0.6	12
644	Nanomaterials-Mediated Immunomodulation for Cancer Therapeutics. <i>Frontiers in Chemistry</i> , 2021, 9, 629635.	1.8	15
645	Prognostic Significance of CD4+ and CD8+ Tumor-Infiltrating Lymphocytes in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis. <i>Cancers</i> , 2021, 13, 781.	1.7	62
646	Phenotype reports: Sharing the knowledge. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2021, 99, 216-217.	1.1	1
647	Longitudinal Immune Profiling Reveals Unique Myeloid and T-cell Phenotypes Associated with Spontaneous Immunoediting in a Prostate Tumor Model. <i>Cancer Immunology Research</i> , 2021, 9, 529-541.	1.6	11
648	Nomograms to Predict the Density of Tumor-Infiltrating Lymphocytes in Patients With High-Grade Serous Ovarian Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 590414.	1.3	10
649	Complementing the Complement: Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 627701.	1.3	22
650	Cancer stem cells and macrophages: molecular connections and future perspectives against cancer. <i>Oncotarget</i> , 2021, 12, 230-250.	0.8	27
651	LincRNA-immunity landscape analysis identifies EPIC1 as a regulator of tumor immune evasion and immunotherapy resistance. <i>Science Advances</i> , 2021, 7, .	4.7	28

#	ARTICLE	IF	CITATIONS
652	Crosstalk between Macrophages, T Cells, and Iron Metabolism in Tumor Microenvironment. <i>Oxidative Medicine and Cellular Longevity</i> , 2021, 2021, 1-14.	1.9	40
653	Importance of the PD-1/PD-L1 Axis for Malignant Transformation and Risk Assessment of Oral Leukoplakia. <i>Biomedicines</i> , 2021, 9, 194.	1.4	25
654	Single-Cell Transcriptome Analysis Identifies Ligand-Receptor Pairs Associated With BCP-ALL Prognosis. <i>Frontiers in Oncology</i> , 2021, 11, 639013.	1.3	4
655	Wnt- $\beta$ -catenin activation epigenetically reprograms Treg cells in inflammatory bowel disease and dysplastic progression. <i>Nature Immunology</i> , 2021, 22, 471-484.	7.0	39
656	High Expression of COX-2 Associated with the Depth of Invasion on Acral Melanoma by Increasing TGF- $\beta$ 1. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2021, Volume 14, 209-216.	0.8	4
657	Prognostic impact of the tumor immune microenvironment in pulmonary pleomorphic carcinoma. <i>Lung Cancer</i> , 2021, 153, 56-65.	0.9	7
658	Relationship between podoplanin-expressing cancer-associated fibroblasts and the immune microenvironment of early lung squamous cell carcinoma. <i>Lung Cancer</i> , 2021, 153, 1-10.	0.9	43
659	Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling. <i>Nature Communications</i> , 2021, 12, 1434.	5.8	46
660	Extracellular Vesicles and Their Role in the Spatial and Temporal Expansion of Tumor-Immune Interactions. <i>International Journal of Molecular Sciences</i> , 2021, 22, 3374.	1.8	9
661	Understanding the Immune-Stroma Microenvironment in B Cell Malignancies for Effective Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 626818.	1.3	13
662	Similarities between Tumour Immune Response and Chronic Wound Microenvironment: Influence of Mesenchymal Stromal/Stem Cells. <i>Journal of Immunology Research</i> , 2021, 2021, 1-11.	0.9	9
663	The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 610303.	1.3	118
664	Anti-Tumor Drug Discovery Based on Natural Product $\beta$ -Elemene: Anti-Tumor Mechanisms and Structural Modification. <i>Molecules</i> , 2021, 26, 1499.	1.7	46
665	Autologous Stem Cell Transplantation for Myeloma: Cytoreduction or an Immunotherapy?. <i>Frontiers in Immunology</i> , 2021, 12, 651288.	2.2	8
666	Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects. <i>Frontiers in Oncology</i> , 2021, 11, 589680.	1.3	23
667	Exploiting bone niches: progression of disseminated tumor cells to metastasis. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	17
668	Silencing of BCSG1 with specific siRNA via nanocarriers for breast cancer treatment. <i>Bulletin Du Cancer</i> , 2021, 108, 323-332.	0.6	2
669	Immune Checkpoint Inhibition as a Strategy in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021, 4, 86-104.	0.6	0

#	ARTICLE	IF	CITATIONS
670	Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?. Trends in Cancer, 2021, 7, 181-185.	3.8	1
671	Natural products targeting into cancer hallmarks: An update on caffeine, theobromine, and (+)-catechin. Critical Reviews in Food Science and Nutrition, 2022, 62, 7222-7241.	5.4	33
672	Insights Gained from Single-Cell Analysis of Immune Cells in the Tumor Microenvironment. Annual Review of Immunology, 2021, 39, 583-609.	9.5	153
673	MHC heterogeneity and response of metastases to immunotherapy. Cancer and Metastasis Reviews, 2021, 40, 501-517.	2.7	12
674	Interfaces between cellular responses to DNA damage and cancer immunotherapy. Genes and Development, 2021, 35, 602-618.	2.7	61
675	Immune checkpoint molecules B7-H6 and PD-L1 co-pattern the tumor inflammatory microenvironment in human breast cancer. Scientific Reports, 2021, 11, 7550.	1.6	9
676	Industrializing engineered autologous T cells as medicines for solid tumours. Nature Reviews Drug Discovery, 2021, 20, 476-488.	21.5	12
678	Predictive biomarkers for response to immune checkpoint inhibition. Seminars in Cancer Biology, 2022, 79, 4-17.	4.3	70
679	Multomics analysis reveals a distinct response mechanism in multiple primary lung adenocarcinoma after neoadjuvant immunotherapy. , 2021, 9, e002312.		21
680	Hypoxia-modulatory nanomaterials to relieve tumor hypoxic microenvironment and enhance immunotherapy: Where do we stand?. Acta Biomaterialia, 2021, 125, 1-28.	4.1	36
681	Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine model. Journal of Nanobiotechnology, 2021, 19, 102.	4.2	27
682	Cancer Stem Cells Are Possible Key Players in Regulating Anti-Tumor Immune Responses: The Role of Immunomodulating Molecules and MicroRNAs. Cancers, 2021, 13, 1674.	1.7	9
683	Centrosome Dynamics and Its Role in Inflammatory Response and Metastatic Process. Biomolecules, 2021, 11, 629.	1.8	5
684	Tumour neoantigen mimicry by microbial species in cancer immunotherapy. British Journal of Cancer, 2021, 125, 313-323.	2.9	29
685	Is immunotherapy in the future of therapeutic management of sarcomas?. Journal of Translational Medicine, 2021, 19, 173.	1.8	18
686	Immuno-Oncological Biomarkers for Squamous Cell Cancer of the Head and Neck: Current State of the Art and Future Perspectives. Cancers, 2021, 13, 1714.	1.7	14
687	Immune Landscape of Thyroid Cancers: New Insights. Frontiers in Endocrinology, 2020, 11, 637826.	1.5	30
688	Immune-Checkpoint Inhibitors in Platinum-Resistant Ovarian Cancer. Cancers, 2021, 13, 1663.	1.7	18

#	ARTICLE	IF	CITATIONS
689	Ropporin-1 and 1B Are Widely Expressed in Human Melanoma and Evoke Strong Humoral Immune Responses. <i>Cancers</i> , 2021, 13, 1805.	1.7	2
690	Construction and Validation of an Immune Infiltration-Related Gene Signature for the Prediction of Prognosis and Therapeutic Response in Breast Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 666137.	2.2	11
691	Natural Killerâ€Dendritic Cell Interactions in Liver Cancer: Implications for Immunotherapy. <i>Cancers</i> , 2021, 13, 2184.	1.7	14
692	Nanoâ€and Microscale Drug Delivery Approaches for Therapeutic Immunomodulation. <i>ChemNanoMat</i> , 2021, 7, 773-788.	1.5	5
693	Prognostic Value of the Tumor Immune Microenvironment for Early-stage, Nonâ€Small Cell Lung Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 350-355.	0.6	3
694	Safety and efficacy of autologous whole cell vaccines in hematologic malignancies: A systematic review and metaâ€analysis. <i>Hematological Oncology</i> , 2021, 39, 448-464.	0.8	7
696	Assessment of Immune Status in Dynamics for Patients with Cancer Undergoing Immunotherapy. <i>Journal of Oncology</i> , 2021, 2021, 1-7.	0.6	2
697	The therapeutic landscape of hepatocellular carcinoma. <i>Med</i> , 2021, 2, 505-552.	2.2	20
698	Alteration of Macrophage Infiltrating Compartment: A Novel View on Oral Carcinogenesis. <i>Pathobiology</i> , 2021, 88, 327-337.	1.9	7
699	A brand new era of cancer immunotherapy: breakthroughs and challenges. <i>Chinese Medical Journal</i> , 2021, 134, 1267-1275.	0.9	15
700	Cancer Salt Nostalgia. <i>Cells</i> , 2021, 10, 1285.	1.8	5
701	Tumor necrosis: A synergistic consequence of metabolic stress and inflammation. <i>BioEssays</i> , 2021, 43, e2100029.	1.2	24
702	Imunoterapia como tratamento de cÃncer e o papel da enfermagem. <i>Research, Society and Development</i> , 2021, 10, e38710615902.	0.0	0
703	Chemopreventive and Anti-tumor Potential of Natural Products in Oral Cancer. <i>Nutrition and Cancer</i> , 2022, 74, 779-795.	0.9	12
704	Challenges targeting cancer neoantigens in 2021: a systematic literature review. <i>Expert Review of Vaccines</i> , 2021, 20, 827-837.	2.0	13
706	A systematic study of novel drug delivery mechanisms and treatment strategies for pancreatic cancer. <i>Journal of Drug Delivery Science and Technology</i> , 2021, 63, 102539.	1.4	9
707	Immunotherapy for Advanced Nonâ€Small Cell Lung Cancer: A Decade of Progress. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e105-e127.	1.8	67
708	Dormant mechanisms reveal the clinical significance of tumor dormancy: a narrative review. <i>Annals of Blood</i> , 0, 6, 15-15.	0.4	0

#	ARTICLE	IF	CITATIONS
709	Memory-like Differentiation Enhances NK Cell Responses to Melanoma. <i>Clinical Cancer Research</i> , 2021, 27, 4859-4869.	3.2	33
710	Beyond Just Peptide Antigens: The Complex World of Peptide-Based Cancer Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 696791.	2.2	58
711	Analyzing the influence of <sc>IL18</sc> in regulation of <sc>YAP1</sc> in breast oncogenesis using <sc>Bioportal</sc>. <i>Cancer Reports</i> , 2022, 5, e1484.	0.6	2
712	Insights Into Dendritic Cells in Cancer Immunotherapy: From Bench to Clinical Applications. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 686544.	1.8	25
713	Eutopic endometrium from women with endometriosis and chlamydial endometritis share immunological cell types and DNA repair imbalance: A transcriptome meta-analytical perspective. <i>Journal of Reproductive Immunology</i> , 2021, 145, 103307.	0.8	8
714	Blockade of HVEM for Prostate Cancer Immunotherapy in Humanized Mice. <i>Cancers</i> , 2021, 13, 3009.	1.7	20
715	Immunology of Lynch Syndrome. <i>Current Oncology Reports</i> , 2021, 23, 96.	1.8	10
716	Long non-coding RNAs XIST and MALAT1 hijack the PD-L1 regulatory signaling pathway in breast cancer subtypes. <i>Oncology Letters</i> , 2021, 22, 593.	0.8	11
717	Identifying novel ovarian tumor biomarkers through mining of the transcriptome of circulating immune cells: A proof-of-concept study. <i>American Journal of Reproductive Immunology</i> , 2021, 86, e13469.	1.2	2
718	Imaging in Tumor Immunology. <i>Nuclear Medicine and Molecular Imaging</i> , 2021, 55, 225-236.	0.6	2
719	Investigational Drug Treatments for Triple-Negative Breast Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 652.	1.1	8
720	PD1-positive exosomes suppress antitumor immunity by inducing tumor-specific CD8 <sup>+</sup> T cell exhaustion during metastasis. <i>Cancer Science</i> , 2021, 112, 3437-3454.	1.7	33
721	Comparing immunotherapies to other frequently used treatments of gastric cancer. <i>Expert Review of Clinical Pharmacology</i> , 2021, 14, 1221-1232.	1.3	2
722	Pan-Cancer Survey of Tumor Mass Dormancy and Underlying Mutational Processes. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 698659.	1.8	3
723	The Immune Heterogeneity Between Pulmonary Adenocarcinoma and Squamous Cell Carcinoma: A Comprehensive Analysis Based on lncRNA Model. <i>Frontiers in Immunology</i> , 2021, 12, 547333.	2.2	13
724	The therapeutic and prognostic implications of immunobiology in colorectal cancer: a review. <i>British Journal of Cancer</i> , 2021, 125, 1341-1349.	2.9	21
725	Innate lymphoid cells and cancer: Role in tumor progression and inhibition. <i>European Journal of Immunology</i> , 2021, 51, 2188-2205.	1.6	22
726	Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review. <i>Immunotherapy</i> , 2021, 13, 989-1000.	1.0	7



#	ARTICLE	IF	CITATIONS
727	Stimuli-Sheddable Nanomedicine Overcoming Pathophysiological Barriers for Potentiating Immunotherapy of Cancer. <i>Journal of Biomedical Nanotechnology</i> , 2021, 17, 1486-1509.	0.5	1
728	Combination strategies of immunotherapy in non-small cell lung cancer: facts and challenges. <i>Chinese Medical Journal</i> , 2021, 134, 1908-1919.	0.9	2
729	Immunity and Breast Cancer: Focus on Eosinophils. <i>Biomedicines</i> , 2021, 9, 1087.	1.4	15
730	Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma. <i>International Journal of Oral Science</i> , 2021, 13, 24.	3.6	107
731	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. , 2021, 9, e002597.		45
733	Role of Virus-Related Chronic Inflammation and Mechanisms of Cancer Immune-Suppression in Pathogenesis and Progression of Hepatocellular Carcinoma. <i>Cancers</i> , 2021, 13, 4387.	1.7	15
734	Ageing and Cancer: The Waning of Community Bonds. <i>Cells</i> , 2021, 10, 2269.	1.8	7
735	CD73 Promotes Tumor Progression in Patients with Esophageal Squamous Cell Carcinoma. <i>Cancers</i> , 2021, 13, 3982.	1.7	11
736	TNF $\pm$ and Immune Checkpoint Inhibition: Friend or Foe for Lung Cancer?. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8691.	1.8	17
737	Higher Enhancement Intrahepatic Nodules on the Hepatobiliary Phase of Gd-EOB-DTPA-Enhanced MRI as a Poor Responsive Marker of Anti-PD-1/PD-L1 Monotherapy for Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , 2021, 10, 615-628.	4.2	31
738	Balance and modulation of immunoediting for cancer treatment using synergistic nano-photo-immuno effects. <i>Nanophotonics</i> , 2021, 10, 3383-3389.	2.9	1
739	Dendrimers for cancer immunotherapy: Avidity-based drug delivery vehicles for effective anti-tumor immune response. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2022, 14, e1752.	3.3	13
740	Microbiome analysis combined with targeted metabolomics reveal immunological anti-tumor activity of icariside I in a melanoma mouse model. <i>Biomedicine and Pharmacotherapy</i> , 2021, 140, 111542.	2.5	21
742	Immunobiology of Melanoma. <i>Clinics in Plastic Surgery</i> , 2021, 48, 561-576.	0.7	5
743	Mathematical modeling approach of cancer immunoediting reveals new insights in targeted-therapy and timing plan of cancer treatment. <i>Chaos, Solitons and Fractals</i> , 2021, 152, 111349.	2.5	3
744	Epigenetic programming of the immune responses in cancer. , 2022, , 197-235.		1
745	Nano drug delivery strategies for the treatment and diagnosis of oral and throat cancers. , 2021, , 75-106.		0
746	Role of immunotherapy in stage IIIA non-small cell lung cancer: a narrative review. <i>Current Challenges in Thoracic Surgery</i> , 0, .	0.2	2

#	ARTICLE	IF	CITATIONS
747	Cutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer. <i>Journal of Immunotherapy</i> , 2021, 44, 49-62.	1.2	7
748	Recent strategies for nano-based PTT combined with immunotherapy: from a biomaterial point of view. <i>Theranostics</i> , 2021, 11, 7546-7569.	4.6	109
749	Neutrophil-to-lymphocyte ratio and mortality in the United States general population. <i>Scientific Reports</i> , 2021, 11, 464.	1.6	131
750	Role of nano-sensitizers in radiation therapy of metastatic tumors. <i>Cancer Treatment and Research Communications</i> , 2021, 26, 100303.	0.7	7
751	Combined photothermal-immunotherapy <i>via</i> poly-tannic acid coated PLGA nanoparticles for cancer treatment. <i>Biomaterials Science</i> , 2021, 9, 6282-6294.	2.6	14
752	Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf. <i>Pharmaceuticals</i> , 2021, 14, 40.	1.7	8
753	Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2021, 27, 25-31.	1.0	12
754	ImmuCellAI: A Unique Method for Comprehensive Cell Subsets Abundance Prediction and its Application in Cancer Immunotherapy. <i>Advanced Science</i> , 2020, 7, 1902880.	5.6	558
755	Class I histone deacetylase inhibition promotes CD8 T cell activation in ovarian cancer. <i>Cancer Medicine</i> , 2021, 10, 709-717.	1.3	14
756	Disseminated Tumor Cells and Dormancy in Breast Cancer Progression. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1220, 35-43.	0.8	17
757	Interleukin-8 in the Tumor Immune Niche: Lessons from Comparative Oncology. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1240, 25-33.	0.8	19
758	Cancer Nanomedicine: Special Focus on Cancer Immunotherapy. , 2021, , 465-508.		2
759	Deciphering the loop of epithelial-mesenchymal transition, inflammatory cytokines and cancer immunoeediting. <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 67-77.	3.2	71
760	Priming and Propagating Anti-tumor Immunity: Focal Hypofractionated Radiation for in Situ Vaccination and Systemic Targeted Radionuclide Theranostics for Immunomodulation of Tumor Microenvironments. <i>Seminars in Radiation Oncology</i> , 2020, 30, 181-186.	1.0	21
761	The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer. <i>Urologic Clinics of North America</i> , 2020, 47, e17-e54.	0.8	39
762	<i>In situ</i> vaccination with nanoparticles for cancer immunotherapy: understanding the immunology. <i>International Journal of Hyperthermia</i> , 2020, 37, 4-17.	1.1	12
763	Establishing a model system for evaluating CAR T cell therapy using dogs with spontaneous diffuse large B cell lymphoma. <i>Oncolmmunology</i> , 2020, 9, 1676615.	2.1	33
767	The diagnostic value of a seven autoantibody panel and a nomogram with a scoring table for predicting the risk of non-small cell lung cancer. <i>Cancer Science</i> , 2020, 111, 1699-1710.	1.7	11

#	ARTICLE	IF	CITATIONS
768	Immunotherapy of multiple myeloma. <i>Journal of Clinical Investigation</i> , 2020, 130, 1565-1575.	3.9	103
769	Bone marrow transplantation generates T cell-dependent control of myeloma in mice. <i>Journal of Clinical Investigation</i> , 2018, 129, 106-121.	3.9	49
770	PD-L1 and Survival in Solid Tumors: A Meta-Analysis. <i>PLoS ONE</i> , 2015, 10, e0131403.	1.1	288
771	Evaluation of Selected Immunomodulatory Glycoproteins as an Adjunct to Cancer Immunotherapy. <i>PLoS ONE</i> , 2016, 11, e0146881.	1.1	7
772	Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2017, 12, e0179536.	1.1	34
773	Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors. <i>PLoS ONE</i> , 2017, 12, e0179726.	1.1	216
774	Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B. <i>Journal of Clinical and Translational Hepatology</i> , 2018, 6, 1-10.	0.7	39
775	Clinicopathological features of programmed cell death-ligand 1 expression in patients with oral squamous cell carcinoma. <i>Open Medicine (Poland)</i> , 2020, 15, 292-301.	0.6	7
776	Current Biochemical Applications and Future Prospects of Chlorotoxin in Cancer Diagnostics and Therapeutics. <i>Advanced Pharmaceutical Bulletin</i> , 2019, 9, 510-520.	0.6	9
777	The roles of homologous recombination and the immune system in the genomic evolution of cancer. <i>Journal of Translational Science</i> , 2018, 5, .	0.2	16
778	The Roles of Autophagy and Senescence in the Tumor Cell Response to Radiation. <i>Radiation Research</i> , 2020, 194, 103.	0.7	51
779	Tumor suppressor maspin as a modulator of host immune response to cancer. <i>Bosnian Journal of Basic Medical Sciences</i> , 2015, 15, 1-6.	0.6	19
780	The Role of Endoplasmic Reticulum Aminopeptidase 1 Biology in Immune Evasion by Tumours. <i>Journal of Vaccines and Immunology</i> , 2015, 1, 028-035.	0.3	3
781	Clinicopathological significance of intratumoral and peritumoral lymphocytes and lymphocyte score based on the histologic subtypes of cutaneous melanoma. <i>Oncotarget</i> , 2017, 8, 14759-14769.	0.8	39
782	<i>Cblb</i> -deficient T cells are less susceptible to PD-L1-mediated inhibition. <i>Oncotarget</i> , 2017, 8, 41841-41853.	0.8	19
783	Prognostic impact of programmed cell death ligand 1 (PD-L1) expression and its association with epithelial-mesenchymal transition in extrahepatic cholangiocarcinoma. <i>Oncotarget</i> , 2018, 9, 20034-20047.	0.8	32
784	Role of tumor microenvironment in ovarian cancer pathobiology. <i>Oncotarget</i> , 2018, 9, 22832-22849.	0.8	54
785	High salt induces P-glycoprotein mediated treatment resistance in breast cancer cells through store operated calcium influx. <i>Oncotarget</i> , 2018, 9, 25193-25205.	0.8	26

#	ARTICLE	IF	CITATIONS
786	Genetic prevention of lymphoma in p53 knockout mice allows the early development of p53-related sarcomas. <i>Oncotarget</i> , 2014, 5, 11924-11938.	0.8	10
787	Prognostic value of immune cells in the tumor microenvironment of early-stage lung cancer: a meta-analysis. <i>Oncotarget</i> , 2019, 10, 7142-7155.	0.8	42
788	Cytokine treatment in cancer immunotherapy. <i>Oncotarget</i> , 2015, 6, 19346-19347.	0.8	17
789	Concepts and mechanisms underlying chemotherapy induced immunogenic cell death: impact on clinical studies and considerations for combined therapies. <i>Oncotarget</i> , 2015, 6, 41600-41619.	0.8	102
790	Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model. <i>Oncotarget</i> , 2016, 7, 18508-18520.	0.8	75
791	Loss of HIF-1 $\alpha$ in macrophages attenuates AhR/ARNT-mediated tumorigenesis in a PAH-driven tumor model. <i>Oncotarget</i> , 2016, 7, 25915-25929.	0.8	11
792	Myeloid leukemia switch as immune escape from CD19 chimeric antigen receptor (CAR) therapy. <i>Translational Cancer Research</i> , 2016, 5, S221-S225.	0.4	21
793	Can Combined Therapy Benefit Immune Checkpoint Blockade Response in Hepatocellular Carcinoma?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2019, 19, 222-228.	0.9	4
794	Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research. <i>Anticancer Research</i> , 2017, 37, 5955-5965.	0.5	45
795	Immunoediting is not a primary transformation event in a murine model of MLL-ENL AML. <i>Life Science Alliance</i> , 2018, 1, e201800079.	1.3	5
796	Nanoparticles for Effective Combination Therapy of Cancer. <i>International Journal of Nanotechnology and Nanomedicine</i> , 2016, 1, .	1.0	11
797	Novel Nuclear Medicine Imaging Applications in Immuno-Oncology. <i>Cancers</i> , 2020, 12, 1303.	1.7	6
798	Emergence of immunotherapy as a novel way to treat hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2018, 24, 1839-1858.	1.4	30
799	Mathematical modeling of tumor growth: the MCF-7 breast cancer cell line. <i>Mathematical Biosciences and Engineering</i> , 2019, 16, 6512-6535.	1.0	21
800	Immune based therapy for melanoma. <i>Indian Journal of Medical Research</i> , 2016, 143, 135.	0.4	19
801	The hallmarks of cancer and their therapeutic targeting in current use and clinical trials. <i>Iraqi Journal of Hematology</i> , 2020, 9, 1.	0.0	6
802	Immunotherapy in breast cancer. <i>Journal of Carcinogenesis</i> , 2019, 18, 2.	2.5	56
803	Antidepressant therapy in patients with cancer: A clinical review. <i>Taiwanese Journal of Psychiatry</i> , 2019, 33, 13.	0.1	8

#	ARTICLE	IF	CITATIONS
804	Cross-talk between tumors can affect responses to therapy. <i>Oncolimmunology</i> , 2015, 4, e975572.	2.1	7
805	Pathogenesis of Cancer: Cancer Reparative Trap. <i>Journal of Cancer Therapy</i> , 2015, 06, 399-412.	0.1	11
806	A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity. <i>BMB Reports</i> , 2020, 53, 512-520.	1.1	17
807	Cancer immunotherapy in clinical practice: the past, present, and future. <i>Chinese Journal of Cancer</i> , 2014, 33, 445-457.	4.9	38
808	A forward genetic screen reveals novel independent regulators of ULBP1, an activating ligand for natural killer cells. <i>ELife</i> , 2015, 4, .	2.8	36
809	Exploration of the prognostic signature reflecting tumor microenvironment of lung adenocarcinoma based on immunologically relevant genes. <i>Bioengineered</i> , 2021, 12, 7417-7431.	1.4	6
811	The Therapeutic Potential of Tackling Tumor-Induced Dendritic Cell Dysfunction in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 724883.	2.2	19
812	The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer. <i>Cancers</i> , 2021, 13, 5004.	1.7	9
813	Effects of Tumor-Derived Exosome Programmed Death Ligand 1 on Tumor Immunity and Clinical Applications. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 760211.	1.8	9
814	Redefining innate natural antibodies as important contributors to anti-tumor immunity. <i>ELife</i> , 2021, 10, .	2.8	12
815	Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction. <i>Acta Biomedica Scientifica</i> , 2021, 6, 146-159.	0.1	0
819	Inflammation and Lung Cancer: Addressing Inflammation with Immunotherapy. , 2015, , 191-209.		0
820	Inflammation Related Cancer - Highlights. <i>Journal of Carcinogenesis &amp; Mutagenesis</i> , 2016, 7, .	0.3	5
821	A Review on Cancer Progression - Related Pineal Endocrine Deficiency: Possible Mechanisms and Clinical Implications. <i>Endocrinology &amp; Metabolic Syndrome: Current Research</i> , 2016, 5, .	0.3	0
822	Les cellules innées lymphoïdes : des nouveaux acteurs de l'immunité. <i>Bulletin De L'Academie Nationale De Medecine</i> , 2016, 200, 561-574.	0.0	0
823	The modulation of Dicer regulates tumor immunogenicity in melanoma. <i>Oncotarget</i> , 2016, 7, 47663-47673.	0.8	3
824	How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, .	0.2	3
825	Renal carcinoma and immunotherapy. <i>Onkologie (Czech Republic)</i> , 2016, 10, 251-255.	0.0	1

#	ARTICLE	IF	CITATIONS
826	Immunoediting. , 2017, , 2212-2215.		0
829	Chronic Mechanistic Target of Rapamycin Inhibition: Preventing Cancer to Delay Aging or Vice Versa?. , 2018, , 1-18.		0
830	Immunosenescence and Cutaneous Malignancies. , 2018, , 185-202.		2
831	Current Status and Issues of PD-L1 Testing in Non-small Cell Lung Cancer. Japanese Journal of Lung Cancer, 2018, 58, 189-195.	0.0	0
833	Medicina perioperatoria in chirurgia oncologica in chiave PNEI: il ruolo delle strategie anestesiolgiche su recupero e prognosi. Pnei Review, 2018, , 104-116.	0.1	0
839	Chronic Mechanistic Target of Rapamycin Inhibition: Preventing Cancer to Delay Aging or Vice Versa?. , 2020, , 111-128.		0
840	The Highs and Lows of Cannabis in Cancer Treatment and Bone Marrow Transplantation. Rambam Maimonides Medical Journal, 2020, 11, e0009.	0.4	0
841	Sialic Acids and TAGs of Tumor Cells to Escape Immune Surveillance and Immune Editing. , 2020, , 169-192.		0
842	Systems Immunology Approach in Understanding the Association of Allergy and Cancer. , 2020, , 53-72.		0
844	CCL11 increases the proportion of CD4+CD25+Foxp3+ Treg cells and the production of IL-2 and TGF- $\beta$ 2 by CD4+ T $\gamma$ 1/2 cells via the STAT5 signaling pathway. Molecular Medicine Reports, 2020, 21, 2522-2532.	1.1	18
845	The Effects of Radiation on Cancer Immunology. Novel Approaches in Cancer Study, 2020, 4, .	0.2	0
846	Inflamatorn-lymfomy. Onkologie (Czech Republic), 2020, 14, 107-107.	0.0	0
847	Extracellular Vesicles and Their Roles in Cancer Progression. Methods in Molecular Biology, 2021, 2174, 143-170.	0.4	82
849	Prognostic landscape of tumor-infiltrating immune cells and immune-related genes in the tumor microenvironment of gastric cancer. Aging, 2020, 12, 17958-17975.	1.4	10
850	MicroRNA-206 promotes the recruitment of CD8 <sup>+</sup> T cells by driving M1 polarisation of Kupffer cells. Gut, 2021, , gutjnl-2021-324170.	6.1	24
851	Opioids and Breast Cancer Recurrence: A Systematic Review. Cancers, 2021, 13, 5499.	1.7	6
852	Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment. World Journal of Clinical Cases, 2020, 8, 5935-5943.	0.3	6
853	Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment. World Journal of Clinical Cases, 2020, 8, 5932-5940.	0.3	0

#	ARTICLE	IF	CITATIONS
854	Fighting microbial pathogens by integrating host ecosystem interactions and evolution. <i>BioEssays</i> , 2021, 43, 2000272.	1.2	5
855	Hypoxic Transformation of Immune Cell Metabolism Within the Microenvironment of Oral Cancers. <i>Frontiers in Oral Health</i> , 2020, 1, 585710.	1.2	5
856	CRISPR Challenges and Opportunities for Space Travel. <i>Space and Society</i> , 2020, , 19-34.	1.6	0
857	Immun-Checkpoint-Inhibition in der Onkologie – Menschenkundliche Betrachtung und Ableitung für die Misteltherapie. <i>Der Merkurstab</i> , 2020, 73, 15-20.	0.0	0
858	Therapeutic Vaccines for Gastrointestinal Malignancies. <i>Diagnostics and Therapeutic Advances in GI Malignancies</i> , 2020, , 113-158.	0.2	1
859	Cyclooxygenase-2 contributes to mutant epidermal growth factor receptor lung tumorigenesis by promoting an immunosuppressive environment. <i>Cancer Translational Medicine</i> , 2020, 6, 40.	0.2	0
860	Cellular Therapy for Melanoma. , 2020, , 1267-1299.		0
861	Use of RNA Interference with TCR Transfer to Enhance Safety and Efficiency. <i>Methods in Molecular Biology</i> , 2020, 2115, 327-349.	0.4	0
862	Immunopathology and Immunotherapy of Central Nervous System Cancer. , 2020, , 379-425.		0
863	Laryngeal Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1296, 79-101.	0.8	3
864	Nanozymes in Tumor Theranostics. <i>Frontiers in Oncology</i> , 2021, 11, 666017.	1.3	20
865	Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity. <i>Journal of Histochemistry and Cytochemistry</i> , 2022, 70, 53-81.	1.3	6
866	Novel insights on use of doxorubicin to treat chemoresistant TNBC by Immunotherapy. <i>International Journal of Immunotherapy and Cancer Research</i> , 2020, , 016-018.	0.4	0
867	Prospects of Cell Immobilization in Cancer Research and Immunotherapy. <i>Gels Horizons: From Science To Smart Materials</i> , 2021, , 165-193.	0.3	0
870	CELL MEDIATED IMMUNITY IN PATIENTS WITH STAGE II–IV COLORECTAL CANCER WITH OR WITHOUT CIRCULATING TUMOR CELLS. <i>Siberian Journal of Oncology</i> , 2020, 19, 94-98.	0.1	0
871	Antibody-drug conjugates: an evolving approach for melanoma treatment. <i>Melanoma Research</i> , 2021, 31, 1-17.	0.6	4
873	Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression. <i>Oncology</i> , 2015, 29, 908-20, 922.	0.4	50
874	Nanoparticles for Effective Combination Therapy of Cancer. , 2016, 1, .		6

#	ARTICLE	IF	CITATIONS
875	How Checkpoint Inhibitors Are Changing the Treatment Paradigm in Solid Tumors: What Advanced Practitioners in Oncology Need to Know. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, 498-509.	0.2	6
877	Immunotherapy: The future of cancer treatment. <i>Journal of Oral and Maxillofacial Pathology</i> , 2021, 25, 371.	0.3	0
878	Xenograft cancer vaccines prepared from immunodeficient mice increase tumor antigen diversity and host T cell efficiency against colorectal cancers. <i>Cancer Letters</i> , 2022, 526, 66-75.	3.2	3
879	Simultaneous disruption of circulating miR-21 and cytotoxic T lymphocytes (CTLs): Prospective diagnostic and prognostic markers for esophageal squamous cell carcinoma (ESCC). <i>Journal of Clinical Laboratory Analysis</i> , 2022, 36, e24125.	0.9	6
880	Introduction on Nuclear Medicine and Immunology. , 2022, , 1-13.		1
881	Imaging Î±-GalCer-Activated iNKT Cells in a Hepatic Metastatic Environment. <i>Cancer Immunology Research</i> , 2022, 10, 12-25.	1.6	2
882	IL-13RÎ±1 Suppresses Tumor Progression in Two-Stage Skin Carcinogenesis Model by Regulating Regulatory T Cells. <i>Journal of Investigative Dermatology</i> , 2022, 142, 1565-1575.e17.	0.3	3
883	T cell landscape and dynamics in immunoglobulin light chain amyloidosis before and after daratumumab-based therapy. <i>Clinical and Translational Medicine</i> , 2021, 11, e582.	1.7	0
884	Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, , .	0.7	4
885	Anti-telomerase immune response predicts disease progression in chronic lymphocytic leukemia. <i>Clinical Immunology Communications</i> , 2021, 1, 35-44.	0.5	0
886	Immunotherapy in Breast Cancer: When, How, and What Challenges?. <i>Biomedicines</i> , 2021, 9, 1687.	1.4	31
887	Intercepting Premalignant, Preinvasive Breast Lesions Through Vaccination. <i>Frontiers in Immunology</i> , 2021, 12, 786286.	2.2	8
888	Chemogenetic modulation of sensory neurons reveals their regulating role in melanoma progression. <i>Acta Neuropathologica Communications</i> , 2021, 9, 183.	2.4	21
889	HLA AND CANCER. <i>Physical and Rehabilitation Medicine Medical Rehabilitation</i> , 0, , .	0.1	0
890	Whole-Cell-Mimicking Carrier-Free Nanovaccines Amplify Immune Responses Against Cancer and Bacterial Infection. <i>Advanced Functional Materials</i> , 2022, 32, 2108917.	7.8	12
891	Transcutaneous Vagal Nerve Stimulation Alone or in Combination With Radiotherapy Stimulates Lung Tumor Infiltrating Lymphocytes But Fails to Suppress Tumor Growth. <i>Frontiers in Immunology</i> , 2021, 12, 772555.	2.2	4
892	Resistance to Immunotherapy: Mechanisms and Means for Overcoming. <i>Advances in Experimental Medicine and Biology</i> , 2021, 1342, 45-80.	0.8	2
893	A Darwinian perspective on tumor immune evasion. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188671.	3.3	6



#	ARTICLE	IF	CITATIONS
896	MALIGNANT TUMORS ASSOCIATED WITH HEREDITARY IMMUNODEFICIENCIES. <i>Voprosy Onkologii</i> , 2018, 64, 7-14.	0.1	0
897	The Multifaceted Effects of Gut Microbiota on the Immune System of the Intestinal Mucosa. <i>Immuno</i> , 2021, 1, 583-594.	0.6	1
898	Gene essentiality for tumour growth influences neoantigen-directed immunoediting. <i>Clinical and Translational Medicine</i> , 2022, 12, e714.	1.7	0
899	Pro-Resolving Factor Administration Limits Cancer Progression by Enhancing Immune Response Against Cancer Cells. <i>Frontiers in Immunology</i> , 2021, 12, 812171.	2.2	3
900	Immunotherapy maintenance therapy for advanced urothelial carcinoma (aUC): a comprehensive review. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1097-1105.	1.2	5
901	Breast Cancer Tumor Microenvironment and Molecular Aberrations Hijack Tumoricidal Immunity. <i>Cancers</i> , 2022, 14, 285.	1.7	12
902	Breast Cancer Vaccines: Disappointing or Promising?. <i>Frontiers in Immunology</i> , 2022, 13, 828386.	2.2	30
903	Impact of Cancer Stem Cells and Cancer Stem Cell-Driven Drug Resiliency in Lung Tumor: Options in Sight. <i>Cancers</i> , 2022, 14, 267.	1.7	11
904	Early onset of severe lymphopenia during definitive radiotherapy correlates with mean body dose and predicts poor survival in cervical cancer. <i>Cancer Biomarkers</i> , 2022, 34, 149-159.	0.8	7
905	Precision medicine to manage chronic immune-related conditions. , 2022, , 295-318.		1
906	Exosomes in cancer immunoediting and immunotherapy. <i>Asian Journal of Pharmaceutical Sciences</i> , 2022, 17, 193-205.	4.3	21
907	Identification of Immune-Related Prognostic mRNA and lncRNA in Patients with Hepatocellular Carcinoma. <i>Journal of Oncology</i> , 2022, 2022, 1-16.	0.6	4
908	The Human Leukocyte Antigen G as an Immune Escape Mechanism and Novel Therapeutic Target in Urological Tumors. <i>Frontiers in Immunology</i> , 2022, 13, 811200.	2.2	7
909	Inflammatory and immune effects on tumor progression. <i>Trends in Immunology</i> , 2022, 43, 93-95.	2.9	1
910	Gamma delta ( $\gamma\delta$ ) T cells in cancer immunotherapy; where it comes from, where it will go?. <i>European Journal of Pharmacology</i> , 2022, 919, 174803.	1.7	23
912	Persistent Changes of Peripheral Blood Lymphocyte Subsets in Patients with Oral Squamous Cell Carcinoma. <i>Healthcare (Switzerland)</i> , 2022, 10, 342.	1.0	8
913	Discovering the Triad between Nav1.5, Breast Cancer, and the Immune System: A Fundamental Review and Future Perspectives. <i>Biomolecules</i> , 2022, 12, 310.	1.8	2
914	New insights into the discovery of drugs for triple-negative breast cancer metastasis. <i>Expert Opinion on Drug Discovery</i> , 2022, 17, 365-376.	2.5	3

#	ARTICLE	IF	CITATIONS
915	Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2022, 15, 17.	6.9	46
917	PD-1 and PD-L1 expression in thyroid follicular epithelial dysplasia: Hashimoto thyroiditis related atypia and potential papillary carcinoma precursor. <i>Apmis</i> , 2022, 130, 276-283.	0.9	3
918	Development of Tumor Mutation Burden-Related Prognostic Model and Novel Biomarker Identification in Stomach Adenocarcinoma. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 790920.	1.8	10
919	Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy. <i>Advanced Science</i> , 2022, 9, e2200027.	5.6	26
920	Tumor cell malignancy: A complex trait built through reciprocal interactions between tumors and tissue-body system. <i>iScience</i> , 2022, 25, 104217.	1.9	6
921	Bacteria as Nanoparticle Carriers for Immunotherapy in Oncology. <i>Pharmaceutics</i> , 2022, 14, 784.	2.0	3
922	Arginase: An emerging and promising therapeutic target for cancer treatment. <i>Biomedicine and Pharmacotherapy</i> , 2022, 149, 112840.	2.5	42
923	Central Role of the Antigen-Presentation and Interferon- $\gamma$ Pathways in Resistance to Immune Checkpoint Blockade. <i>Annual Review of Cancer Biology</i> , 2022, 6, 85-102.	2.3	15
924	Immune Cell-Derived Extracellular Vesicles – New Strategies in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 771551.	2.2	44
925	Current Advancements of Plant-Derived Agents for Triple-Negative Breast Cancer Therapy through Deregulating Cancer Cell Functions and Reprogramming Tumor Microenvironment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13571.	1.8	8
926	Survival Advantage Following TAG-72 Antigen-Directed Cancer Surgery in Patients With Colorectal Carcinoma: Proposed Mechanisms of Action. <i>Frontiers in Oncology</i> , 2021, 11, 731350.	1.3	5
927	Multifunctional Immunoliposomes Enhance the Immunotherapeutic Effects of PD-1 Antibodies against Melanoma by Reprogramming Immunosuppressive Tumor Microenvironment. <i>Small</i> , 2022, 18, e2105118.	5.2	8
928	Dynamic Change of Soluble Interleukin-2 Receptor Distinguished Diffuse Large B-Cell Lymphoma with Prognostic Significance and Tumor Microenvironment. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
929	The soluble form of CD160 acts as a tumor mediator of immune escape in melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2731-2742.	2.0	6
930	Consideration of possible effects of vitamin D on established cancer, with reference to malignant melanoma. <i>Pigment Cell and Melanoma Research</i> , 2022, 35, 408-424.	1.5	8
940	Immunotherapy: The future of cancer treatment. <i>Journal of Oral and Maxillofacial Pathology</i> , 2021, 25, 371.	0.3	10
941	Tumor infiltrating lymphocytes in head and neck squamous cell carcinoma – Evaluation and clinical impact. <i>Journal of Cancer Research and Therapeutics</i> , 2022, 18, 49-54.	0.3	3
942	The Genetic Basis of Dormancy and Awakening in Cutaneous Metastatic Melanoma. <i>Cancers</i> , 2022, 14, 2104.	1.7	6

#	ARTICLE	IF	CITATIONS
943	The Leading Role of the Immune Microenvironment in Multiple Myeloma: A New Target with a Great Prognostic and Clinical Value. <i>Journal of Clinical Medicine</i> , 2022, 11, 2513.	1.0	15
944	Spatial Characterization of Tumor-Infiltrating Lymphocytes and Breast Cancer Progression. <i>Cancers</i> , 2022, 14, 2148.	1.7	22
945	TMPRSS2 Serves as a Prognostic Biomarker and Correlated With Immune Infiltrates in Breast Invasive Cancer and Lung Adenocarcinoma. <i>Frontiers in Molecular Biosciences</i> , 2022, 9, 647826.	1.6	8
946	Obesity modulates the immune macroenvironment associated with breast cancer development. <i>PLoS ONE</i> , 2022, 17, e0266827.	1.1	7
947	Exosome-Derived Non-Coding RNAs in the Tumor Microenvironment of Colorectal Cancer: Possible Functions, Mechanisms and Clinical Applications. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	3
948	Tumor-infiltrating lymphocyte therapy for lung cancer and its future paradigms. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 735-745.	1.4	4
949	PD-L1 Expression in Bladder Cancer and Correlation with Tumor Grade, Stage and Outcome. <i>Oman Medical Journal</i> , 0, , .	0.3	1
950	Immunotherapy for Colorectal Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2022, , .	0.9	1
951	Update in TIGIT Immune-Checkpoint Role in Cancer. <i>Frontiers in Oncology</i> , 2022, 12, .	1.3	19
952	Phosphoinositide 3-kinase/Akt and its related signaling pathways in the regulation of tumor-associated macrophages polarization. <i>Molecular and Cellular Biochemistry</i> , 2022, 477, 2469-2480.	1.4	10
953	The Association between the Pan-Immune-Inflammation Value and Cancer Prognosis: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2022, 14, 2675.	1.7	43
954	Modeling cancer immunoeediting in tumor microenvironment with system characterization through the ising-model Hamiltonian. <i>BMC Bioinformatics</i> , 2022, 23, .	1.2	7
955	Recent Applications of Artificial Intelligence from Histopathologic Image-Based Prediction of Microsatellite Instability in Solid Cancers: A Systematic Review. <i>Cancers</i> , 2022, 14, 2590.	1.7	17
956	Natural killer cells and acute myeloid leukemia: promises and challenges. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2849-2867.	2.0	5
957	Extracellular Vesicles and Hepatocellular Carcinoma: Opportunities and Challenges. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	8
958	Intratumorally anchored cytokine therapy. <i>Expert Opinion on Drug Delivery</i> , 2022, 19, 725-732.	2.4	11
959	Circ_0092012 knockdown restrains non-small cell lung cancer progression by inhibiting cell malignant phenotype and immune escape through microRNA-635/programmed death ligand 1 axis. <i>Bioengineered</i> , 2022, 13, 13929-13943.	1.4	0
960	Virus-Based Immuno-Oncology Models. <i>Biomedicines</i> , 2022, 10, 1441.	1.4	4

#	ARTICLE	IF	CITATIONS
961	Emerging Biomaterials Imaging Antitumor Immune Response. <i>Advanced Materials</i> , 2022, 34, .	11.1	22
962	Resveratrol in Cancer Treatment with a Focus on Breast Cancer. <i>Current Molecular Pharmacology</i> , 2023, 16, 346-361.	0.7	2
963	Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas. <i>Cancers</i> , 2022, 14, 3037.	1.7	6
964	Cancer Immunotherapy and Cytotoxicity: Current Advances and Challenges. , 0, , .		0
967	Roles of Tenascin-XB in the Glioma Immune Microenvironment. <i>BIO Integration</i> , 2023, 4, .	0.9	1
968	Immunotherapy: an alternative promising therapeutic approach against cancers. <i>Molecular Biology Reports</i> , 2022, 49, 9903-9913.	1.0	17
969	Multiplex Immunofluorescence and the Digital Image Analysis Workflow for Evaluation of the Tumor Immune Environment in Translational Research. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	12
970	Imbalanced gut microbiota fuels hepatocellular carcinoma development by shaping the hepatic inflammatory microenvironment. <i>Nature Communications</i> , 2022, 13, .	5.8	68
971	Immune surveillance in glioblastoma: Role of the <sc>NKG2D</sc> system and novel cell-based therapeutic approaches. <i>Scandinavian Journal of Immunology</i> , 2022, 96, .	1.3	13
972	A Proposed Link Between Acute Thymic Involution and Late Adverse Effects of Chemotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	5
973	Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 903-914.	1.1	1
974	MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma. <i>Biomolecules</i> , 2022, 12, 930.	1.8	2
975	Stromal and Immune Cell Dynamics in Tumor Associated Tertiary Lymphoid Structures and Anti-Tumor Immune Responses. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	3
976	The SRPK inhibitor N-(2-(piperidin-1-yl)-5-(trifluoromethyl)phenyl) isonicotinamide (SRPIN340) increases the immune response against metastatic melanoma in mice. <i>Biochemical Pharmacology</i> , 2022, 203, 115161.	2.0	6
977	Icariside I " A novel inhibitor of the kynurenine-AhR pathway with potential for cancer therapy by blocking tumor immune escape. <i>Biomedicine and Pharmacotherapy</i> , 2022, 153, 113387.	2.5	5
978	Volatile and Intravenous Anesthetics and Cancer. , 2023, , 128-139.		0
979	Stepwise Size Shrinkage Cascade-Activated Supramolecular Prodrug Boosts Antitumor Immunity by Eliciting Pyroptosis. <i>Advanced Science</i> , 2022, 9, .	5.6	35
980	Geospatial Immune Heterogeneity Reflects the Diverse Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma. <i>Cancer Discovery</i> , 2022, 12, 2350-2371.	7.7	28

#	ARTICLE	IF	CITATIONS
982	The expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
983	Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma. <i>Biomarker Research</i> , 2022, 10, .	2.8	1
984	Splenic irradiation contributes to gradeÂ°¥Á3 lymphopenia after adjuvant chemoradiation for stomach cancer. <i>Clinical and Translational Radiation Oncology</i> , 2022, 36, 83-90.	0.9	3
985	Salmonella-induced immune response reduces recurrence and tumor dissemination in preclinical melanoma model. <i>Current Research in Immunology</i> , 2022, 3, 159-166.	1.2	0
986	Increasing Immune Dysfunction is Associated with Increasing Matrix-Metalloproteinase-2 Expression and Predicts Biochemical Failure in Men with Bone Marrow Micro-Metastasis Positive Localized Prostate Cancer. <i>Asian Pacific Journal of Cancer Prevention</i> , 2022, 23, 2497-2505.	0.5	4
987	Matrix proteoglycans in tumor inflammation and immunity. <i>American Journal of Physiology - Cell Physiology</i> , 2022, 323, C678-C693.	2.1	5
988	Immunotherapy in non-small cell lung cancer: Past, present, and future directions. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	32
989	Stromal remodeling regulates dendritic cell abundance and activity in the tumor microenvironment. <i>Cell Reports</i> , 2022, 40, 111201.	2.9	9
990	Construction of a solid Cox model for AML patients based on multiomics bioinformatic analysis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	4
991	The Roles of Immune Cells in Gastric Cancer: Anti-Cancer or Pro-Cancer?. <i>Cancers</i> , 2022, 14, 3922.	1.7	9
992	High density of CD8 T cell and immune imbalance of T lymphocytes subsets are associated with proliferative verrucous leukoplakia. <i>Immunology</i> , 2023, 168, 96-109.	2.0	4
993	Triple negative breast cancer: Pitfalls and progress. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	110
994	Bioinformatic analysis of RNA-seq data from TCGA database reveals prognostic significance of immune-related genes in colon cancer. <i>Medicine (United States)</i> , 2022, 101, e29962.	0.4	0
995	Immunotherapy in Advanced NSCLC Without Driver Mutations: Available Therapeutic Alternatives After Progression and Future Treatment Options. <i>Clinical Lung Cancer</i> , 2022, 23, 643-658.	1.1	5
996	AQP9 transports lactate in tumor-associated macrophages to stimulate an M2-like polarization that promotes colon cancer progression. <i>Biochemistry and Biophysics Reports</i> , 2022, 31, 101317.	0.7	2
997	CD200 ectodomain shedding into the tumor microenvironment leads to NK cell dysfunction and apoptosis. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	13
998	Biphenyl-based small molecule inhibitors: Novel cancer immunotherapeutic agents targeting PD-1/PD-L1 interaction. <i>Bioorganic and Medicinal Chemistry</i> , 2022, 73, 117001.	1.4	9
999	Molecular imaging of immune checkpoints in oncology: Current and future applications. <i>Cancer Letters</i> , 2022, 548, 215896.	3.2	5

#	ARTICLE	IF	CITATIONS
1000	Immunotherapy for Pediatric Cancer. , 2022, , 1-38.		1
1001	Management of Patients with Cardiac Toxicity: The Point of View of the Oncologist. Current Clinical Pathology, 2022, , 91-111.	0.0	0
1002	Interdisciplinary Approach in Gastrointestinal Cancers. , 2022, , 1-16.		0
1003	Risk-Based Breast Cancer Prognosis Using Minimal Patient Characteristics. , 2022, , .		0
1004	Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy. ELife, 0, 11, .	2.8	23
1005	miR-uculous new avenues for cancer immunotherapy. Frontiers in Immunology, 0, 13, .	2.2	0
1006	Tipping the scales: Immunotherapeutic strategies that disrupt immunosuppression and promote immune activation. Frontiers in Immunology, 0, 13, .	2.2	5
1007	Prognostic characteristics of immune subtypes associated with acute myeloid leukemia and their identification in cell subsets based on single-cell sequencing analysis. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	1
1008	Antibody-Drug Conjugates for Melanoma and Other Skin Malignancies. Current Treatment Options in Oncology, 2022, 23, 1428-1442.	1.3	1
1009	The new progress in cancer immunotherapy. Clinical and Experimental Medicine, 2023, 23, 553-567.	1.9	6
1010	Tissue-resident glial cells associate with tumoral vasculature and promote cancer progression. Angiogenesis, 0, , .	3.7	2
1011	Tumor Microenvironment in Hepatocellular Carcinoma: Key Players for Immunotherapy. Journal of Hepatocellular Carcinoma, 0, Volume 9, 1109-1125.	1.8	11
1012	CD45RO+TILs: cellular biomarkers for larynx squamous cell carcinoma outcome. Brazilian Journal of Otorhinolaryngology, 2022, 88, S133-S142.	0.4	1
1013	Mechanosensitive Ion Channel PIEZO1 Signaling in the Hall-Marks of Cancer: Structure and Functions. Cancers, 2022, 14, 4955.	1.7	5
1015	The Association of Immunotherapy With the Overall Survival of Inoperable Stage III Non-small Cell Lung Cancer Patients Who Do not Receive Chemoradiation. Journal of Immunotherapy, 0, Publish Ahead of Print, .	1.2	1
1016	The association of cervicovaginal Langerhans cells with clearance of human papillomavirus. Frontiers in Immunology, 0, 13, .	2.2	3
1017	Molecular profiling of core immune-escape genes highlights LCK as an immune-related prognostic biomarker in melanoma. Frontiers in Immunology, 0, 13, .	2.2	8
1018	Genomic instability, origin and evolution of cancer, and personalized immunotherapy. Vacunas (English Edition), 2022, 23, 222-233.	0.3	0

#	ARTICLE	IF	CITATIONS
1019	Hazard Function Analysis of Recurrence in Patients with Curatively Resected Lung Cancer: Results from the Japanese Lung Cancer Registry in 2010. <i>Cancers</i> , 2022, 14, 5119.	1.7	0
1020	Tbc1d10c is a selective, constitutive suppressor of the CD8 T-cell anti-tumor response. <i>OncImmunology</i> , 2022, 11, .	2.1	3
1021	Effect of the m6ARNA gene on the prognosis of thyroid cancer, immune infiltration, and promising immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	3
1022	Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers. <i>Trends in Immunology</i> , 2022, 43, 932-946.	2.9	22
1023	The Tumor Microenvironment. <i>Environmental Chemistry for A Sustainable World</i> , 2022, , 1-49.	0.3	0
1024	Potential roles of hyaluronic acid in <i>in vivo</i> CAR T cell reprogramming for cancer immunotherapy. <i>Nanoscale</i> , 2022, 14, 17821-17840.	2.8	2
1025	Newest Approaches in Immunotherapy for Non-Hodgkin's Lymphoma. <i>European Medical Journal</i> (Chelmsford, England), 0, , 40-48.	3.0	0
1026	Nanoparticle Enhancement of Natural Killer (NK) Cell-Based Immunotherapy. <i>Cancers</i> , 2022, 14, 5438.	1.7	8
1027	Immunology of Oral Squamous Cell Carcinoma – A Comprehensive Insight with Recent Concepts. <i>Life</i> , 2022, 12, 1807.	1.1	1
1028	Regulation of Metastatic Tumor Dormancy and Emerging Opportunities for Therapeutic Intervention. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13931.	1.8	6
1029	Antitumor efficacy of multi-target <i>in situ</i> vaccinations with CpG oligodeoxynucleotides, anti-OX40, anti-PD1 antibodies, and aptamers. <i>Journal of Biomedical Research</i> , 2023, 37, 194.	0.7	1
1030	Chapter 13. The Intersection of Biomaterials, Tissue Engineering, and Immuno-oncology. <i>Biomaterials Science Series</i> , 2022, , 342-383.	0.1	0
1031	Prognostic role of inflammatory diets in colorectal cancer overall and in strata of tumor-infiltrating lymphocyte levels. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	4
1032	Expression of HLA class I is associated with immune cell infiltration and patient outcome in breast cancer. <i>Scientific Reports</i> , 2022, 12, .	1.6	2
1033	Identification of TCR rearrangements specific for genetic alterations in EGFR-mutated non-small cell lung cancer: results from the ADJUVANT-CTONG1104 trial. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	2.0	1
1034	Exposure of Immunogenic Tumor Antigens in Surrendered Immunity and the Significance of Autologous Tumor Cell-Based Vaccination in Precision Medicine. <i>International Journal of Molecular Sciences</i> , 2023, 24, 147.	1.8	1
1035	Chasing Uterine Cancer with NK Cell-Based Immunotherapies. <i>Future Pharmacology</i> , 2022, 2, 642-659.	0.6	3
1036	Improving the efficiency of identifying malignant pulmonary nodules before surgery via a combination of artificial intelligence CT image recognition and serum autoantibodies. <i>European Radiology</i> , 2023, 33, 3092-3102.	2.3	3

#	ARTICLE	IF	CITATIONS
1037	Radiopharmaceuticals heat anti-tumor immunity. <i>Theranostics</i> , 2023, 13, 767-786.	4.6	4
1038	Thiolate DNazymes on Gold Nanoparticles for Isothermal Amplification and Detection of Mesothelioma-derived Exosomal PD-L1 mRNA. <i>Analytical Chemistry</i> , 2023, 95, 3228-3237.	3.2	2
1039	A Literature Review in Immuno-Oncology: Pathophysiological and Clinical Features of Colorectal Cancer and the Role of the Doctor-Patient Interaction. <i>Journal of Cancer Therapy</i> , 2022, 13, 654-684.	0.1	1
1040	Meta-hallmarks of aging and cancer. <i>Cell Metabolism</i> , 2023, 35, 12-35.	7.2	80
1041	Tumor-infiltrating lymphocyte enrichment predicted by CT radiomics analysis is associated with clinical outcomes of non-small cell lung cancer patients receiving immune checkpoint inhibitors. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
1042	Quantities of CD3+, CD8+ and CD56+ lymphocytes decline in breast cancer recurrences while CD4+ remain similar. <i>Diagnostic Pathology</i> , 2023, 18, .	0.9	0
1043	Facts and Perspectives: Implications of tumor glycolysis on immunotherapy response in triple negative breast cancer. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	2
1044	MHC II immunogenicity shapes the neoepitope landscape in human tumors. <i>Nature Genetics</i> , 2023, 55, 221-231.	9.4	5
1045	Novel Strategies for the Bioavailability Augmentation and Efficacy Improvement of Natural Products in Oral Cancer. <i>Cancers</i> , 2023, 15, 268.	1.7	9
1046	Analysis of C-X-C motif chemokine receptors in breast cancer: potential value in immunotherapy and prognostic prediction. <i>Annals of Translational Medicine</i> , 2022, 10, 1379-1379.	0.7	0
1047	In Vitro Evidence of Differential Immunoregulatory Response between MDA-MB-231 and BT-474 Breast Cancer Cells Induced by Bone Marrow-Derived Mesenchymal Stromal Cells Conditioned Medium. <i>Current Issues in Molecular Biology</i> , 2023, 45, 268-285.	1.0	1
1048	A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	8
1049	Single-nucleus RNA sequencing and deep tissue proteomics reveal distinct tumour microenvironment in stage-I and II cervical cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2023, 42, .	3.5	5
1050	Understanding the squamous cell carcinoma immune microenvironment. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	7
1051	Selective COX-2 Inhibitor Etoricoxib's Liposomal Formulation Attenuates M2 Polarization of TAMs and Enhances its Anti-metastatic Potential. <i>Pharmaceutical Research</i> , 2023, 40, 551-566.	1.7	1
1052	HLA-G: A Novel Immune Checkpoint for Solid Cancer Immunotherapy. , 2023, , 1-27.		0
1053	Combining <i>in situ</i> vaccination and immunogenic apoptosis to treat cancer. <i>Immunotherapy</i> , 2023, 15, 367-381.	1.0	3
1055	Oncogenic drivers dictate immune control of acute myeloid leukemia. <i>Nature Communications</i> , 2023, 14, .	5.8	2



#	ARTICLE	IF	CITATIONS
1057	The Interaction of Programmed Cell Death Protein and Its Ligands with Non-Coding RNAs in Neoplasms: Emerging Anticancer Immunotherapeutics. <i>Processes</i> , 2023, 11, 538.	1.3	0
1058	Clinical relevance of PD-1 positive CD8 T-cells in gastric cancer. <i>Gastric Cancer</i> , 2023, 26, 393-404.	2.7	4
1059	Clinical Significance of Tumour-Infiltrating B Lymphocytes (TIL-Bs) in Breast Cancer: A Systematic Literature Review. <i>Cancers</i> , 2023, 15, 1164.	1.7	4
1060	Killer to cure: Expression and production costs calculation of tobacco plant-made cancer immune checkpoint inhibitors. <i>Plant Biotechnology Journal</i> , 2023, 21, 1254-1269.	4.1	4
1061	Cancer Initiation and Inflammation. , 2023, , 1-15.		0
1062	The role of tumor activation and inhibition with saturation effects in a mathematical model of tumor and immune system interactions undergoing oncolytic viral therapy. <i>Mathematical Methods in the Applied Sciences</i> , 2023, 46, 10787-10813.	1.2	1
1063	Tumor Evasion of the Immune System: Role of Interferon and Tumor Necrosis Factor in Cancer. , 2022, , 1-27.		0
1064	IFN $\gamma$ is a central node of cancer immune equilibrium. <i>Cell Reports</i> , 2023, 42, 112219.	2.9	6
1065	Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5208.	1.8	4
1066	Cutaneous Squamous Cell Carcinoma in Immunocompromised Patientsâ€”A Comparison between Different Immunomodulating Conditions. <i>Cancers</i> , 2023, 15, 1764.	1.7	5
1067	Immunotherapy for hepatocellular carcinoma: Recent advances and future targets. , 2023, 244, 108387.		12
1068	Immunotherapy: A new target for cancer cure (Review). <i>Oncology Reports</i> , 2023, 49, .	1.2	0
1069	Roles of cancer stem cells in cancer immune surveillance. <i>Minerva Biotechnology and Biomolecular Research</i> , 2023, 35, .	0.3	0
1070	Overcoming the Limitations of Therapeutic Strategies to Combat Pancreatic Cancer Using Nanotechnology. <i>Current Cancer Drug Targets</i> , 2023, 23, .	0.8	1
1071	Worth a Pound of Cure? Emerging Strategies and Challenges in Cancer Immunoprevention. <i>Cancer Prevention Research</i> , 2023, 16, 483-495.	0.7	1
1072	Early detection of lung cancer in a real-world cohort via tumor-associated immune autoantibody and imaging combination. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1073	Luteolin-Zn Complex Inhibits Invasion and Migration of M2-Like TAMs via the Downregulation of <i>AMPK/mTOR</i> and <i>PI3K/Akt/mTOR</i> Signaling Pathway Under Hypoxia. <i>Natural Product Communications</i> , 2023, 18, 1934578X2311679.	0.2	0
1074	Immunotherapy in Prostate Cancer: Recent Advances and Future Directions. <i>European Medical Journal Urology</i> , 0, , 51-61.	0.0	5

#	ARTICLE	IF	CITATIONS
1075	Cancer immune escape: the role of antigen presentation machinery. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 8131-8141.	1.2	6
1076	Novel strategies for cancer immunotherapy: counter-immunoediting therapy. <i>Journal of Hematology and Oncology</i> , 2023, 16, .	6.9	14
1077	Bioinformatics analysis of the genes associated with co-occurrence of heart failure and lung cancer. <i>Experimental Biology and Medicine</i> , 2023, 248, 843-857.	1.1	0
1078	<i>Biology of Cancer</i> . , 2023, , 86-186.		0
1079	<i>Cancer Surveillance</i> . , 2023, , 271-341.		0
1080	Clonogenicity-based radioresistance determines the expression of immune suppressive immune checkpoint molecules after hypofractionated irradiation of MDA-MB-231 triple-negative breast cancer cells. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
1081	Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances. <i>Pathology Research and Practice</i> , 2023, 246, 154470.	1.0	0
1090	Immunology and immunotherapy in gastric cancer. <i>Clinical and Experimental Medicine</i> , 2023, 23, 3189-3204.	1.9	1
1091	<i>Immunotherapy for Pancreatic Cancer</i> . , 2023, , 1-27.		0
1101	Safety and efficacy of immune checkpoint inhibitors after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 0, , .	1.3	0
1114	Roles of circRNAs in regulating the tumor microenvironment. , 2023, 40, .		1
1115	Nanomedicine – Immune System Interactions: Limitations and Opportunities for the Treatment of Cancer. <i>Handbook of Experimental Pharmacology</i> , 2023, , .	0.9	0
1122	Types of Cancers, Epidemiology, and Molecular Insights. , 2024, , 1-36.		0
1134	Epigenetic Regulation in Breast Cancer Tumor Microenvironment. <i>Epigenetics and Human Health</i> , 2023, , 213-243.	0.2	0
1135	In Vitro Evaluation of Cancer Cell Immunogenicity and Antigen-Specific T-Cell Cytotoxicity by Flow Cytometry. <i>Methods in Molecular Biology</i> , 2024, , 13-28.	0.4	0
1139	Recent Advances of RNA m6A Modifications in Cancer Immunoediting and Immunotherapy. <i>Cancer Treatment and Research</i> , 2023, , 49-94.	0.2	0
1162	Mitochondria driven innate immune signaling and inflammation in cancer growth, immune evasion, and therapeutic resistance. <i>International Review of Cell and Molecular Biology</i> , 2024, , .	1.6	0